Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Bleeding in patients and mice with Alagille syndrome: sex differences and risk factors

Simona Hankeova, Noemi Van Hul, Jakub Laznovsky, Naomi Hensen, Elvira Verhoef, Tomas Zikmund, Feven Dawit, Michaela Kavkova, Jakub Salplachta, Liting Li, Marika Sjöqvist, Bengt R. Johansson, Mohamed Hassan, View ORCID ProfileVitezslav Bryja, View ORCID ProfileUrban Lendahl, Andrew Jheon, Jian She Wang, Florian Alten, Kristina Teär Fahnehjelm, Björn Fischler, Jozef Kaiser, View ORCID ProfileEmma R. Andersson
doi: https://doi.org/10.1101/2021.04.13.439679
Simona Hankeova
1Dept of Biosciences and Nutrition, Karolinska Institutet, Sweden
2Dept of Experimental Biology, Masaryk University, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noemi Van Hul
3Dept of Cell and Molecular Biology, Karolinska Institutet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakub Laznovsky
5CEITEC – Central European Institute of Technology, Brno University of Technology, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naomi Hensen
3Dept of Cell and Molecular Biology, Karolinska Institutet
4University of Applied Sciences Utrecht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elvira Verhoef
3Dept of Cell and Molecular Biology, Karolinska Institutet
4University of Applied Sciences Utrecht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Zikmund
5CEITEC – Central European Institute of Technology, Brno University of Technology, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feven Dawit
6Dept of Pediatrics, Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaela Kavkova
5CEITEC – Central European Institute of Technology, Brno University of Technology, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakub Salplachta
5CEITEC – Central European Institute of Technology, Brno University of Technology, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liting Li
7Children’s Hospital of Fudan University, Shanghai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marika Sjöqvist
1Dept of Biosciences and Nutrition, Karolinska Institutet, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bengt R. Johansson
8EM Unit, Institute of Biomedicine, University of Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Hassan
11University of San Francisco, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vitezslav Bryja
2Dept of Experimental Biology, Masaryk University, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vitezslav Bryja
Urban Lendahl
3Dept of Cell and Molecular Biology, Karolinska Institutet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Urban Lendahl
Andrew Jheon
11University of San Francisco, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian She Wang
7Children’s Hospital of Fudan University, Shanghai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Alten
9Dept of Ophthalmology, University of Muenster Medical Center, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristina Teär Fahnehjelm
10Department of Pediatric Ophthalmology, strabismus, electrophysiology and ocular oncology, St. Erik Eye Hospital, and Department of Clinical Neuroscience, Karolinska Institutet, both Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Björn Fischler
6Dept of Pediatrics, Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jozef Kaiser
5CEITEC – Central European Institute of Technology, Brno University of Technology, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma R. Andersson
1Dept of Biosciences and Nutrition, Karolinska Institutet, Sweden
3Dept of Cell and Molecular Biology, Karolinska Institutet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emma R. Andersson
  • For correspondence: emma.andersson@ki.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

Alagille syndrome (ALGS) is generally thought of as a pediatric cholestatic liver disease, but spontaneous bleeds are a major cause of death. Here, we investigated bleeding in patients and a mouse model for ALGS (Jag1Ndr/Ndr mice) and asked whether phenotypes identified in mice could be detected in patients non-invasively. Jag1Ndr/Ndr mice spontaneously bled, exhibiting a thin skull and vascular defects. Vascular abnormalities included artery-vein crossings, tortuous vessels, and capillary breakdown. Furthermore, Jag1Ndr/Ndr arteries had sparse vascular smooth muscle cell coverage, which was further aggravated by hypertension. Retinographs from patients with ALGS, biliary atresia, or CADASIL confirmed tortuous blood vessels and artery-vein crossings in ALGS. We also identified sex-specific differences: fewer major vessels in female Jag1Ndr/Ndr mice, and four-fold more female than male patients with intracranial hemorrhage. In conclusion, dysfunctional Jag1 disrupted vascular growth and homeostasis, with sex-specific differences. The mouse model for Alagille syndrome demonstrated multiple bleeding risk factors and vascular defects that can be identified in patients non-invasively.

Introduction

Alagille syndrome (ALGS) is characterized by liver and heart defects, as well as vertebral abnormalities, characteristic faces, and posterior embryotoxon (a white line visible through a clear cornea caused by a thickened Schwalbe’s ring) 1–3. In addition to these hallmark features, 9% manifest non-cardiac vascular features such as vascular stenosis, Moyamoya syndrome, or absence of specific vessels, and up to 15% experience spontaneous intracranial hemorrhage 3–6. Vascular defects are also a significant cause of transplant-associated complications 6. Bleeding in patients with ALGS is a major cause of death in this group, in which up to 25% of deaths can be attributed to intracranial hemorrhage 3,6,7. Bleeding may occur spontaneously, or upon minor head trauma, and is not correlated with liver-disease-induced coagulopathy 8. In cases of minor head trauma leading to hemorrhage, cranial bone has been described as inordinately thin 4,9, sometimes associated with “thin-walled arteries” 4,9,10.

ALGS is a genetic disorder caused by mutations in the Notch ligand JAGGED1 or in rare cases in NOTCH2 receptor (ALGS1; Online Mendelian Inheritance in Man/OMIM no. 118450, and ALGS2, OMIM no. 610205) 11–13. Notch signaling is a major blood vessel regulator, and Notch1/3/4 receptors, Delta like (Dll) 1/4 and Jagged1 (Jag1) ligands have key roles in endothelial cell (EC) growth, proliferation, arterial specification, and mural cell recruitment 14–16. Appropriate angiogenesis and vascular homeostasis are essential for organism health. Notch pathway mutations are the cause of at least two congenital diseases with vascular involvement: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL, mutations in NOTCH3) 17 and Adams Oliver syndrome (mutations in NOTCH1, DLL4 or RBPJk 18–21, for review see 22). The tight association of Notch mutations with congenital vascular diseases underscores the need for appropriate animal models of Notch-mutant development and disease, in which to test potential therapies.

We recently developed a mouse model for ALGS, Jag1Ndr/Ndr mice, which recapitulates the hallmark hepatic and cardiac features of ALGS 23. In this report, we explored whether Jag1Ndr/Ndr mice provided insights into cellular mechanisms contributing to vascular compromise and uncovered potential risk factors for vascular events in patients with ALGS.

Despite cholestatic liver disease, Jag1Ndr/Ndr mice did not display coagulopathy, as assessed by a Thrombin Anti-Thrombin (TAT) assay. Instead, bleeding in Jag1Ndr/Ndr mice could be attributed to a combination of skull thinning, female sex, abnormal vascular development and vascular compromise. Our data recapitulated previous reports of the role of Jag1 in vascular development, including reduced endothelial vascular outgrowth, decreased branching and fewer tip cells. Novel phenotypes, specific to Jag1Ndr/Ndr mice, were a thinner skull, and vascular defects such as aberrant arteriovenous crossings, tortuous vessels and degenerating retinal intermediate plexus capillaries. Jag1Ndr/Ndr arterioles exhibited poor vascular smooth muscle cell coverage (VSMC), which was exacerbated with age or upon an increase in blood pressure, resulting in thin-walled arteries and occasionally an aneurysm. Although sparse VSMC coverage was reminiscent of CADASIL, blood vessels in patients with ALGS showed significant defects in vessel numbers and venous tortuosity, while patients with CADASIL did not show defects in these analyses. Jag1Ndr/Ndr mice are thus a useful model to study ALGS-related skull and vascular defects and could be used to test potential treatments. Importantly, vascular pathology could be quantified non-invasively in retinographs from patients with ALGS, suggesting fundus photography should be further investigated as a predictive biomarker for vascular health and bleeding in this pediatric population.

Results

Patients with Alagille syndrome exhibit sporadic spontaneous and provoked hemorrhages, with sex-differences

Previous studies have shown that vascular defects are common in ALGS, but have not identified any sex differences in disease presentation 6,10,24. First, we asked which vascular events were most often identified in patients, and whether vascular events were affected by sex. To test whether sex impacted on bleeding events, we retrospectively analyzed a cohort of 156 patients with ALGS from the Children’s Hospital of Fudan University. In this cohort, the frequency of intracranial bleeds was 3.21% (3 males of 94 males, and 2 females of 62 females). There were no overt sex differences in this patient cohort, though the low frequency of bleeds, and low numbers of patients with bleeds, limits comparisons. The most common type of bleeding events were intracranial bleeding and upper gastrointestinal bleeding (Table 1). In order to methodically map vascular defects in a larger group of patients with vascular events, we performed a systematic literature search, and identified 150 patients with ALGS and a vascular structural abnormality (e.g. stenosis, aneurysm or occlusion) or with a spontaneous/provoked bleed or ischemic event (Figure 1A – C, Supp Table 1, for search terms and strategy see Material and methods). The most commonly reported structural abnormalities were stenosis, aneurysm and Moyamoya (Figure 1B). Stenosis (61/150, 41%)10,24–59 (Figure 1B), was equally prevalent among males and females. Forty-five patients (45/150, 29.3%) 25,26,28,29,31–34,37,38,44,45,47–49,52,53,56,59,60 were reported with abdominal region vessel stenosis and twenty-nine patients (29/150, 19%) 10,24,26,28,35,40,41,43,44,47,48,50,54,57–59 were reported with head and neck arterial stenosis, of which six patients had both (6/150, 4%) 26,28,44,47,48,59. The predominant form of stenosis (apart from pulmonary artery stenosis) was renal artery stenosis (23/150, 15.3%) 26,28,29,31–33,37,38,44,45,49,52,53,56,59–61, followed by aortic stenosis or coarctation (22/150, 14.7%) 25,27,29–36,38,39,42,44,46,47,51,53,55,59,62,63, internal carotid stenosis (16/150, 10.7%) 10,24,26,35,40,41,43,50,54,58 and celiac artery stenosis (11/150, 7.3%) 25,26,32,34,47–49. The second most commonly reported structural abnormality was an aneurysm (26/150 patients, 17.3%) (Figure 1B), mostly in the basilary (8/150 patients, 5.3%) 24,32,37,39,58,64, abdominal (8/150 patients, 5.3%) 31,32,39,49,60,65 and carotid (7/150 patients, 4.7%) 10,24,39,48,66,67 arteries. Vessel agenesis and hypoplasia (10 males vs 6 females, 1.7x more) 24,25,28,29,33,38,41,42,58,68–71 and esophageal varices were most reported in male patients (6 males vs 3 females, 2x more) 26,30,67,72–77 and patent ductus arteriosus was more highly reported in female patients (7 females vs 2 males, 3.5x more) 37,38,42,45,63,78–81 (Figure 1B). Esophageal varices develop secondary to portal hypertension and can lead to gastrointestinal bleeding 82. The most frequently reported functional events were bleeding events (55/150, 36.7%) and intracranial infarctions (12/150, 8%) 10,24,41,48,83,84 (Figure 1C). Among the bleeding events, the predominantly reported type was intracranial bleeding (25/150, 16.7%) 24,38,39,51,64,65,67,79,85–91, followed by pulmonary hemorrhage (15/150, 10%) 45,92. Other bleeding events included gastrointestinal (10/150, 6.7%) 9,26,73,74,76,77,93–96, nasal (2/150, 1.3%) 61,73 intrathoracic 97, intraperitoneal 98, renal 60, and ocular 89 bleeding, as well as hematochezia 73, hematuria 48 and hematemesis 61 (each 1/150, 0.7%) (Figure 1D). Intracranial bleeds included hematoma (generally induced by a head trauma due to thin skull), and hemorrhages (Figure 1E). Hematoma was reported equally frequently for males and females 9,24,39,64,85,86,88,91, whereas more females were reported with intracranial hemorrhages (12 females vs 3 males, 4x more, Figure 1E) 24,38,39,51,64,65,67,79,85–90.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1. Vascular bleeds in a cohort of 156 patients from Children’s Hospital of Fudan University.

F, female; M, male; y, year;

Figure 1.
  • Download figure
  • Open in new tab
Figure 1. Patients with Alagille syndrome exhibit sporadic spontaneous and provoked hemorrhages, with sex-differences.

(A) Systematic review search strategy that identified 91 relevant publications describing 150 individuals with Alagille syndrome (ALGS) and vascular events (excluding pulmonary artery stenosis) including sex data. (B) Structural vascular abnormalities grouped by prevalence in male or female patients with ALGS. (C) Functional vascular abnormalities grouped by prevalence in male or female patients with ALGS. The numbers next to the graph bars in B and C depict the number of individuals reported with a given anomaly per sex. Some patients had multiple vascular events and are included in several categories. For references and full details, see also Supplementary Table 1. (D) Fifty-five patients were reported with 59 bleeding events, most often intracranial (IC) bleeds. (E) Intracranial bleeds (25 patients) included 10 patients with hematoma (top chart) and 15 with hemorrhage (bottom chart). Pie graphs depict male/female distribution for hematoma and hemorrhage, with the number of reported patients as an inset. ALGS, Alagille syndrome; GI, gastrointenstinal; IC, intracranial; PAS, pulmonary artery stenosis.

Our data confirm previous reports that vascular events, including intracranial hemorrhage, are present in pediatric patients, and suggest that sex may impact on the likelihood of specific types of vascular events. Importantly, females with ALGS are reported four times more frequently with intracranial hemorrhages compared to males with ALGS.

Cholestatic Jag1Ndr/Ndr mice exhibit normal coagulation but a thinner skull and sporadic spontaneous and provoked hemorrhages

To investigate mechanisms contributing to bleeds, and whether the recently reported Jag1Ndr/Ndr mouse model for ALGS mimicked risk factors reported in patients, we next explored known factors associated with bleeding events, including coagulopathy and fragile intracranial bones. We assessed coagulation activity by measuring the levels of Thrombin-Antithrombin (TAT) complexes in blood plasma. TAT levels are usually elevated in cholestasis in both mice and humans indicating liver disease-induced disrupted coagulation function 99,100. At postnatal day 10 (P10), all Jag1Ndr/Ndr mice were jaundiced and cholestatic (Figure 2A and 23), but there were no consistent differences in coagulation function at this stage (Figure 2B). Next we investigated the skull of adult Jag1Ndr/Ndr mice using micro computed tomography (μCT), since thin cranial bone was reported in patients with ALGS with intracranial bleeds 4,9. A qualitative analysis of the Jag1Ndr/Ndr skulls revealed craniosynostosis in all Jag1Ndr/Ndr mice examined (n=3) (Figure 2C, green arrowhead), which was previously described in patients with ALGS 3,24,101. We evaluated the thickness of the cranial bones, focusing on the full thickness (Figure 2C middle panels) and the compact bone (Figure 2C right panels), and found that Jag1Ndr/Ndr cranial bones were thinner. The parietal bone of Jag1Ndr/Ndr mice was thinner compared to the wild type mice, and often consisted of a single layer of compact bone, rather than two layers of compact bone encasing the spongy bone and trabeculae. This is clear when comparing, in wild type mice, the solid color in the middle panel (full thickness width, with corresponding cross-section at right) to the speckled pattern in the right panel (shortest distance width = top layer of compact bone separated from bottom layer by trabeculae, notable in corresponding cross-section at right). In contrast, Jag1Ndr/Ndr parietal bone had similar widths in the whole width and the shortest width/compact bone analyses. To quantitatively assess the changes in the cranial bone, we first measured the length of the skull from the occipital bone (back of the skull) to the nasal bone. Jag1Ndr/Ndr pups are strikingly smaller than wild type animals 23 however, the Jag1Ndr/Ndr adult skull lengths were similar in size to wild types and were, on average, 94.4% of the wild type skull lengths (Figure 2D, p=0.0652). However, the volume of the Jag1Ndr/Ndr cranial bone full width (Figure 2E, ~ 80% of wild type volume) and the compact bone (Figure 2F, ~ 78% of wild type volume) were both significantly lower than wild type skull volumes. The greater decrease in the cranial bone volume compared to length (Figure 2D – F, 80% vs 94%), and the bone fusion seen in parietal bone (Figure 2C) suggest a thinner skull in Jag1Ndr/Ndr mice.

Figure 2.
  • Download figure
  • Open in new tab
Figure 2. Cholestatic Jag1Ndr/Ndr mice exhibit normal coagulation but a thinner skull and sporadic spontaneous and provoked hemorrhages.

(A) Total bilirubin levels in plasma at P10. (B) Thrombin Antithrombin (TAT) enzyme-linked immunosorbent assay (ELISA) from plasma of postnatal day 10 (P10) mice. (C) Micro computed tomography (μCT) of adult skulls (left panel), the green arrowhead marks fused sutures in Jag1Ndr/Ndr mice. Color map depicting wall thickness of periosteum. Dotted line highlights the area magnified in boxed region at right (middle panel). Color map depicting wall thickness of compact bone, including trabeculae (diploë). Dotted line highlights the area magnified in boxed region (right panel) in which diploë was excluded (black spaces in bone). Scale bar 2 mm. (D) Occipital to nasal bone skull length. (E) The total volume of intracranial periosteum (based on wall thickness analysis). (F) The total volume of intracranial compact bone (excluding diploë, based on wall thickness analysis). (G) Blood vessel permeability assessed by intravenous Evans blue assay. Evans blue was extracted from the kidney, (H) heart and (I) liver. (J) Resin injection into the portal vein followed by (K) quantification of resin leakage outside of the blood vessels (in red) in adult mice. Scale bar 1 mm. (L) Blood brain barrier permeability tested by Evans blue assay of the adult brain parenchyma. (M) Brain from P3 Jag1Ndr/Ndr pup, which died due to brain hemorrhages (n = 2 of 53 Jag1Ndr/Ndr mice). (N) Pup survival analysis between P0 and P10. Each dot represents the absolute percent of remaining animals in the group. (O) P15 Jag1Ndr/Ndr mouse with spontaneous retinal bleeding. Scale bar 20 μm. (P) Red blood cells present outside the arterial vessel wall in P10 Jag1Ndr/Ndr retina. Statistical significance was tested with unpaired Students t-tests (A, B, D – I, K, L) and survival analysis (N). Each dot represents quantifications from one animal in (A, B, D – I, K, L); graphs depict mean values ± standard deviation; p < 0.05 (*), p < 0.01 (**). μCT, micro computed tomography; OD, optical density; TAT, Thrombin Antithrombin; P, postnatal.

In order to test bleeding and blood vessel permeability in the kidney, heart and liver, we used an Evans Blue assay. There was a mild, non-statistically significant, increase in kidney vessel leakage in adult Jag1Ndr/Ndr mice (p=0.0632) (Figure 2G), in which three of five Jag1Ndr/Ndr mice displayed higher Evans blue values in kidney than the highest wild type values. Evans blue values were similar for wild type and Jag1Ndr/Ndr mice in heart and liver (Figure 2H, I), though this interpretation should consider that one wild type also showed unusually high leakage of Evans blue. As a further measure of blood vessel resilience, we analyzed blood vessel leakage from synthetic resin injections into the hepatic portal vein 102. One of four Jag1Ndr/Ndr mice (a female) had 21x more resin outside of the portal vein than control animals, with macroscopically obvious leakage (leaks pseudo colored red, Figure 2J, K). The three Jag1Ndr/Ndr mice with no/less extravasated resin were males.

In order to explore central nervous system vascular accidents, we next examined the brain and the retina. Evans blue injection revealed that two adult Jag1Ndr/Ndr mice (two females, the remaining three animals were males), of five tested, had slightly increased Evan blue leakage in the brain compared to the wild type animals, but on average there was no difference (Figure 2L). Fifty-three Jag1Ndr/Ndr pups were monitored daily from birth until postnatal day 10 (P10), and in this group macroscopically obvious brain hemorrhages occurred in 2 Jag1Ndr/Ndr pups (3.77%) but were not observed in wild type or heterozygous mice (Figure 2M). Survival data were collected for 16 of the Jag1Ndr/Ndr pups, and in addition to one pup dying as a result of a macroscopic brain bleed (one of the 2/53 reported above), six pups were lost to analysis (deaths = 7/16, 43.8%, Figure 2N). These Jag1Ndr/Ndr pups generally died between P1 – P6, and were cannibalized by the mothers, preventing analysis (Figure 2N). In surviving pups at P10 and P15, Jag1Ndr/Ndr pups also sporadically displayed retinal hemorrhage (Figure 2O) or leaky retinal arterioles (Figure 2P).

In summary, our data show that a small percentage (ca 3-4%) of patients with ALGS and Jag1Ndr/Ndr mice exhibit central nervous system bleeds. Taken together, Jag1Ndr/Ndr mice recapitulate spontaneous and rare bleeds in different organs, in the absence of coagulation defects. Similar to the patients, skull thinning in Jag1Ndr/Ndr mice may have contributed to nervous system bleeds.

Delayed retinal vascular outgrowth and remodeling in Jag1Ndr/Ndr mice

JAG1 is a proangiogenic ligand balancing the number of tip cells and stalk cells 103. We therefore investigated retinal sprouting angiogenesis in the mouse model for ALGS. The retina is part of the central nervous system and is vascularized postnatally in mice: during the first fifteen days after birth three capillary plexuses are established in the tissue (schematic Figure 3A, S – superficial, I – intermediate and D – deep capillary plexus)104. At P5, retinal blood vessels in Jag1Ndr/Ndr mice were significantly delayed in outgrowth, a defect that was not symmetric between left and right eyes (Figure 3B, C). The delayed extension and growth persisted throughout angiogenesis, marked by delayed vertical sprouting to the deep capillary plexus at P10 (Supp Figure 1A), and reduced extension of the intermediate capillary plexus at P15 (Supp Figure 1B, green). The number of tip cells was significantly decreased at the vascular front at P5 (Figure 3D left panels, Figure 3E), while the remaining tip cells in Jag1Ndr/Ndr mice displayed an increase in tips per tip cell, with filopodia extending in several directions per cell (Figure 3D blue arrowheads in right panels, Figure 3F). The overall number of filopodia per tip or tip cell was similar in wild type and Jag1Ndr/Ndr mice (Supp Figure 1C).

Figure 3.
  • Download figure
  • Open in new tab
Figure 3. Delayed retinal vascular outgrowth and remodeling in Jag1Ndr/Ndr mice.

(A) Schematic depicting retinal angiogenesis between postnatal day 0 (P0) and P15. During the first 15 days after birth, three capillary plexuses are established S – superficial, I – intermediate, D – deep capillary plexus. (A) Jag1Ndr/Ndr retinal vasculature stained for CD31 (Pecam1) was delayed in outgrowth, quantified in (B). Scale bar 100 μm. (C) Immunofluorescence staining of vascular front at P5 with endothelial tip cells (boxed region). White arrowhead marks example of a tip cell, quantified in (D). Blue arrowheads label tips (bundles of filopodia) of tip cells quantified in (E). Scale bar 20 μm. (F) Retinal vasculature at postnatal day 5 (P5), (G) P10 and (H) P15. Scale bars 20 μm (F), 50 μm (G, H). (I – L) Quantification across retinal blood vessel development at P5, P10 and P15 of (I) vascular length per field, (J) number of endothelial cells (ERG+) per field, (K) number of endothelial cells (ERG+) per vascular length and (L) number of branching points per field. (M) Delta like 4 (DLL4) immunofluorescence in the vascular front at P5. Scale bar 20 μm. White brackets denotes area with high Dll4 intensity. (N) Dll4 relative mRNA levels in whole retina lysates. Statistical significance was tested by unpaired Students t-test (B, D, E, N) or two-way ANOVA (I – L, difference between genotypes), followed by multiple comparison (I – L, differences at individual stages). Each dot represents quantification from one animal; graphs depict mean values ± standard deviation; p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). D, deep capillary plexus; I, intermediate capillary plexus; P, postnatal; S, superficial capillary plexus.

We analyzed vascular plexus remodeling during angiogenesis at P5, P10 and P15 (Figure 3G – M), and total vascular length per field was significantly shorter at P5, but not at P10 or P15, in Jag1Ndr/Ndr retinas (Figure 3G – J), indicating both delayed outgrowth and reduced remodeling. The total vascular length reflected differences in EC numbers, as evidenced by a significant decrease in ERG+ ECs at P5 in Jag1Ndr/Ndr mice (Figure 3G – J, K). The number of ECs normalized to vascular length was similar between Jag1Ndr/Ndr and wild type mice (Figure 3L), suggesting the delayed outgrowth (Figure 3B, C) is not due to migratory defects. The number of branching points was significantly lower at P5 in Jag1Ndr/Ndr retinas but similar at P10 and P15 (Figure 3G – J, M). To determine whether the differences in blood vessel outgrowth were a consequence of altered proliferation, we quantified the number of phosphorylated histone 3 (PH3) and Pecam1 (CD31) double positive cells per area, in 200 μm long zones (in total 12 zones) from the optic nerve (Supp Figure 1D, scheme). The number of proliferating cells was significantly lower in Jag1Ndr/Ndr mice at P5, and the bell-shaped proliferation curve peak was in Zone 4 (800 μm from the optic nerve) in Jag1Ndr/Ndr mice, while the peak was in Zone 5 (1,000 μm from the optic nerve) in wild type mice (Supp Figure 1E). At P10 and P15 the number of proliferating ECs was lower in both Jag1Ndr/Ndr and wild type retinas, and their distribution was similar (Supp Figure 1F, 1G). At P15, the Jag1Ndr/Ndr vascular front had reached the retina periphery and the Jag1Ndr/Ndr vascular length was similar to wild types (Supp Figure 1G and data not shown).

JAG1 competes with the ligand DLL4 for the NOTCH1 receptor 103 and loss of JAG1 leads to upregulation of DLL4 103,105. Analysis of Dll4 expression revealed that DLL4 protein expression was highest in the vascular front and in tips cells in Jag1+/+ mice while it was more widespread in the Jag1Ndr/Ndr vascular front (Figure 3N, white brackets) and Dll4 mRNA levels in Jag1Ndr/Ndr whole retina lysates were significantly increased (Figure 3O). Taken together, our results corroborated the view that JAG1 is necessary for correct angiogenesis, specifically for blood vessel outgrowth, branching, remodeling and proliferation, as reported previously for the EC-specific Jag1 knockout 103. This may reflect a Notch gain of function phenotype via excess DLL4 signaling, as reported previously 103. Our analysis further revealed that, although Jag1Ndr/Ndr tip cells are reduced in number, they form hyperbranched elongated tips. Finally, despite the delay in proliferation and outgrowth at P5, the Jag1Ndr/Ndr superficial vasculature plexus was normalized by P15.

Jag1Ndr/Ndr mice display vascular guidance defects, with fewer and more tortuous blood vessels

Abnormal blood vessel growth or patterning can cause changes in blood flow leading to vessel occlusion 106, changes in shear stress 107 and changes to the vessel wall 108. We analyzed the presence of arteriovenous crossings (Figure 4A), which are considered pathological in mouse retina 109,110, and found a mean value of two arteriole/venule crossings per Jag1Ndr/Ndr retina in both males and females (Figure 4A, B). Jag1Ndr/Ndr females had significantly fewer arterioles (Figure 4C) and venules (Figure 4D) compared to female Jag1+/+ mice, and fewer venules compared to Jag1Ndr/Ndr males (Figure 4D). Another pathological feature associated with changes in vessel walls, aneurysms, hypertension and aging, is vessel tortuosity 108. Arterial tortuosity was increased in two of four Jag1Ndr/Ndr mice at P30 (Figure 4E) and in two of three Jag1Ndr/Ndr mice at one year (Figure 4F), but the overall differences were not statistically significant. In contrast, overall venous tortuosity was significantly increased in Jag1Ndr/Ndr mice independent of age (Figure 4G, 4H). Together, our data demonstrate patterning defects in major arterioles and venules of Jag1Ndr/Ndr mice, with reduced numbers of vessels, and increased tortuosity, with sex-specific differences in the number of major arterioles and venules.

Figure 4.
  • Download figure
  • Open in new tab
Figure 4. Jag1Ndr/Ndr mice display vascular guidance defects, with fewer and more tortuous blood vessels.

(A) Radial arrangement of arterioles (magenta) and venules (green) from the optic nerve. White arrowheads label arteriovenous crossings in Jag1Ndr/Ndr retina. Scale bar left and middle panels 50 μm, and right panel 20 μm. (B) The number of arteriovenous crossings per retina grouped by genotype and sex. (C, D) Quantification of (C) major arterioles and (D) venules coming from the optic nerve head, grouped by genotype and sex. (E, F) Measurement of arterial tortuosity at (E) postnatal day 30 (P30) and at (F) 1 year. (G, H) Measurement of venous tortuosity at (G) P30 and at (H) 1 year. Statistical significance was tested by unpaired Students t-test (E – H) and two-way ANOVA followed by multiple comparison (B – D). Each dot represents quantifications from one animal; graphs depict mean value ± standard deviation; p < 0.05 (*), p < 0.01 (**). A, arteriole; AV, arteriovenous; αSMA, alpha smooth muscle actin; F, female; M, male; P, postnatal; V, venule.

Jag1Ndr/Ndr mice display sparse vascular smooth muscle cell coverage of arteries with large apoptotic gaps in old mice

Blood vessels are composed of two principal cell types: endothelial cells and mural cells, which include VSMCs and pericytes. The foremost Notch-related vascular disorder CADASIL (caused by mutations in NOTCH3) is characterized by poor arterial VSMC coverage 85 and in some cases is associated with neurovascular dementia 112. JAG1 also regulates arterial VSMC maturation and maintenance 103,113,114 and a ruptured aneurysm in a patient with ALGS suggested VSMC loss 115. We therefore investigated VSMCs and pericytes (another type of mural cell required for blood brain/retina barrier integrity 116) in Jag1Ndr/Ndr mice and compared these to known CADASIL or Notch3 mutant phenotypes.

In adult mice, CD13 positive pericytes were not reduced in Jag1Ndr/Ndr retinas compared to Jag1+/+ retinas (Supp Figure 2A), comparable to previous reports for Notch3-/- mice 16. We therefore focused on VSMC development and homeostasis. At P10, α smooth muscle cell actin (αSMA) positive VSMCs covered Jag1+/+ arterioles, with VSMCs oriented perpendicular to the blood vessel axis, while in Jag1Ndr/Ndr retinas VSMC coverage was not as high and cells exhibited a more migratory morphology with their cellular axis parallel to the blood vessel axis (Figure 5A, boxed regions). Adult Jag1Ndr/Ndr mice (at 3 – 6 months) displayed sparse VSMC arteriole coverage, with clear gaps between VSMCs and stenoses (green arrowheads) (Figure 5B). By one year of age, Jag1Ndr/Ndr arteriolar VSMCs degenerated, resulting in αSMA-weak (Figure 5C blue arrowheads) or negative (Figure 5C white arrowheads) areas. αSMA negative areas were sometimes associated with aneurysms in Jag1Ndr/Ndr arterioles (Figure 5C white arrows, also note the enlarged ECs). To determine whether the sparse VSMC coverage, identified using immunofluorescence, indeed reflected gaps between VSMCs we further analyzed VSMC morphology and arteriolar coverage using transmission electron microscopy of retinal and cardiac blood vessels. Retinal Jag1+/+ arteriolar VSMCs were present in a uniform layer surrounding the endothelial cells with wide VSMC-VSMC contacts (Figure 5D, VSMCs pseudocolored in magenta and ECs in green, white arrowheads refer to VSMC contacts). In contrast, retinal Jag1Ndr/Ndr arteriolar VSMCs were sparse, thin, and not in contact with neighboring VSMCs (Figure 5D, white arrowheads show ends of VSMC not in contact with another VSMC). These data confirmed that narrow and widely spaced αSMA bands across arterioles (Figure 5B, C) reflected a thinner VSMC layer with fewer contacts. The VSMCs in Jag1Ndr/Ndr coronary arteries displayed similar gaps (Supp Figure 2B, white arrowheads), suggesting this VSMC defect is not specific to the nervous system. The tight junctions between ECs were normal in Jag1Ndr/Ndr mice (Figure 5D, Supp Figure 2B, green arrowheads). Arteriole diameter appeared greater in one-year-old Jag1Ndr/Ndr retinas (Figure 5C), with thinning of VSMCs and ECs at 3 – 6 months (Figure 5B, D) suggesting a loss of a vascular tone. Although all Jag1Ndr/Ndr mice displayed an increase in arterial diameter compared to wild types, this difference was not statistically significant (p = 0.0536), (Figure 5E). No change in venous diameter was detected in one-year-old Jag1Ndr/Ndr retinas (Figure 5F). To investigate whether the changes in VSMCs could be due to altered JAG1 – NOTCH3 levels, we analyzed JAG1 and NOTCH3 protein expression on arterioles (Supp Figure 2C). JAG1 levels were significantly increased in Jag1Ndr/Ndr ECs and VSMCs (Supp Figure 2C, D), in line with our previous report that dysfunctional JAG1NDR accumulates in vivo 117. NOTCH3 protein levels were similar in Jag1+/+ and Jag1Ndr/Ndr arterioles (Supp Figure 2C, E) and Notch3 mRNA levels were similar in whole retina lysates (Supp Figure 2F).

Figure 5.
  • Download figure
  • Open in new tab
Figure 5. Jag1Ndr/Ndr mice display sparse vascular smooth muscle cell coverage of arteries with large apoptotic gaps in old mice.

(A) Alpha smooth muscle actin (αSMA) coverage of postnatal day 10 (P10) retinal arterioles, boxed regions highlight vascular smooth muscle cells orientation. In Jag1Ndr/Ndr arterioles the VSMCs were oriented parallel to the blood vessel axis, rather than perpendicular and encircling the retinal. (B) Small gaps in αSMA VSMCS coverage of retinal arterioles in 3 – 6 months old mice. Green arrowhead labels focal arterial narrowing/stenosis. (C) αSMA coverage of one-year-old retinal arterioles. One-year-old Jag1Ndr/Ndr mice arterioles display weaker αSMA coverage (blue arrowheads), αSMA negative gaps (white arrowheads) and an aneurysm (white arrows). Cropped images were placed on a black background for esthetic purposes. Scale bar (A – C) 10 μm. (D) Transmission electron microscopy of retinal arterioles. VSMCs color-coded in magenta, endothelial cells (EC) in green. Scale bar 5 μm, boxed region 1 μm. White arrowheads label the edges of VSMCs and the distance between vascular smooth muscle cells. Green arrowheads label EC tight junctions. (E) Diameter measurements of one-year-old retinal arterioles (p = 0.0536), and (F) venules (p=0.2690). (G) Cleaved caspase 3 (cCasp3) immunofluorescence staining of apoptotic cells in one-year-old retinal arterioles. Boxed region is a magnification of an aneurysm in a Jag1Ndr/Ndr arteriole, note the distended endothelial cells. Scale bar 10 μm. (H – J) Quantifications of (H) branching points per field, (I) number of cCasp3 positive cells associated with a branching point and (J) number of cCasp3 positive cells per field, excluding those associated with branching point. Statistical significance was tested using unpaired Students t-test (E, F, H – J). Each dot represents one animal; graphs depict mean values ± standard deviation; p < 0.05 (*), p < 0.01 (**). A, arteriole; αSMA, alpha smooth muscle actin; cCasp3, cleaved caspase 3; P, postnatal; V, venule.

To determine whether the changes in VSMC coverage led to reactivity in the parenchyma we evaluated the distribution and morphology of astrocytes. The astrocytes surrounding Jag1Ndr/Ndr arterioles were increased in density (Supp Figure 2G, 2I) and displayed numerous reactive bundles (Supp Figure 2G, white arrowheads). The astrocytes surrounding venules were similar in distribution in Jag1+/+ and Jag1Ndr/Ndr retinas (Supp Figure 2H, J).

We next explored whether the αSMA negative regions in one-year-old mice were due to cells undergoing apoptosis. We quantified the number of cleaved Caspase 3 positive (cCasp3+) cells along the vessels in VSMCs, or associated with a branching point in ECs, since increased apoptosis was previously shown in VSMCs along the vascular length and in ECs at branch points in Notch3 mutant mice 16. At this stage, the number of branch points was normal in Jag1Ndr/Ndr arterioles (Figure 5G, H). Surprisingly, Jag1Ndr/Ndr arterioles displayed fewer cCasp3+ ECs at branching points (Figure 5I) but significantly more cCasp3+ along the arteriole length, often associated with αSMA negative areas (Figure 5G, J). In sum, Jag1Ndr/Ndr arterioles presented with sparse vascular VSMCs that died via apoptosis, sometimes associated with aneurysm formation. Our results thus demonstrate that JAG1 contributed to arteriole VSMC maturation and maintenance.

Capillary homeostasis is compromised and retinal ganglion cells break down in Jag1Ndr/Ndr retinas

Blood vessel homeostasis is crucial for the integrity of the blood retina/brain barrier and tissue health, and could be a factor contributing to bleeding in ALGS. A mature vascular plexus is characterized by vessel quiescence 118 and by the presence of mural cells, which were abrogated in Jag1Ndr/Ndr mice (Figure 5 and Supp Figure 2). We therefore investigated adult retinal blood vessel homeostasis in Jag1Ndr/Ndr mice. We studied all three retinal vascular plexuses in 3 – 6 month old mice, (Figure 6A), and while the superficial capillary plexus was equally branched in both Jag1+/+ and Jag1Ndr/Ndr retinas (Figure 6A, B), the Jag1Ndr/Ndr intermediate capillary plexus was less vascularized (Figure 6C) with significantly fewer branching points (Figure 6D). To understand how age impacted on vasculature in this model, we analyzed all three retinal vascular plexuses in one-year-old mice (Figure 6E). Both the superficial (Figure 6F) and the intermediate capillary plexuses were equally branched and vascularized (Figure 6G, H) in Jag1+/+ and Jag1Ndr/Ndr retinas. The vascularization of the adult (3 – 6 months) Jag1Ndr/Ndr retina (Figure 6B – D) was thus similar to the one-year-old Jag1+/+ retina (Figure 6F – H) with diminished branching and vascular density in the intermediate capillary plexus.

Figure 6.
  • Download figure
  • Open in new tab
Figure 6. Capillary homeostasis is compromised, and retinal ganglion cells break down in Jag1Ndr/Ndr retinas.

(A) Pseudocolored classification of the three CD31+ capillary layers in adult retina (3 – 6 months old). Scale bar 50 μm. (B) Number of branching points in the superficial capillary plexus (SCP) of adult mice. (C) Vascular length per field in the intermediate capillary plexus (ICP) in adult mice. (D) Number of branching points per field in the ICP in adult mice. (E) Pseudocolored classification of the three CD31+ capillary layers in one-year-old retina. Scale bar 50 μm. (F) Number of branching points per field in SCP in one-year-old mice. (G) Quantification of vascular length per field in ICP in one-year-old mice. (H) Number of branching points per field in ICP in one-year-old mice. (I) Immunofluorescence staining of collagen IV (COLIV) and CD31 in ICP identifies regressed COLIV positive/CD31 negative capillaries (arrowheads). Scale bar 50 μm. (J) Quantification of empty collagen IV sleeve length per field in ICP. (K) Side view of all the retinal capillary plexuses in 3 – 6 months old (top panels) and one-year-old mice (bottom panels). The ICP in old Jag1Ndr/Ndr mice was discontinuous, labeled by white arrowheads. The SCP is labeled with a blue arrowhead, the ICP with a green arrowhead and the DCP with a magenta arrowhead. (L, M) Number of vertical sprouts between SCP (S) and ICP (I) and ICP (I) and DCP (D) in (L) adult and (M) one-year-old mice. (N, O) Retinal ganglion cell axons stained with Neurofilament (NF) at (N) postnatal day 10 (P10) and (O) P40. Unspecific staining of blood is labelled with white arrowheads. (P) Quantification of area covered by NF in P40 mice. Statistical significance was tested using unpaired Students t-test (B – D, F – H, J, P) or two-way ANOVA followed by multiple comparisons (L, M). Each dot represents quantifications from one animal; Graphs depict mean values ± standard deviation; p < 0.05 (*), p < 0.01 (**). COLIV, collagen IV; D or DCP, deep capillary plexus; I or ICP, intermediate capillary plexus; NF, neurofilament; S or SCP, superficial capillary plexus; P, postnatal.

The vascularization of the intermediate capillary plexus at P15 in Jag1Ndr/Ndr retinas was incomplete (Supp Figure 1B), hence it was not clear whether the lower vascular length and lower number of branching points in adult Jag1Ndr/Ndr retinas reflected a persistence of a developmental defect, or whether capillaries had retracted. When a blood vessel retracts, it leaves behind its basal membrane containing Collagen IV (COLIV)15. In order to explore if the differences in the intermediate capillary plexus density were a result of capillary regression, we stained for COLIV (Figure 6I) and measured the lengths of empty COLIV sleeves. Empty COLIV sleeves were 1.7x longer in the Jag1Ndr/Ndr intermediate capillary plexus (Figure 6J), but this difference was not statistically significant. We further quantified the number of vertical sprouts between the superficial and the intermediate (S – I) capillary plexuses and the intermediate and the deep (I – D) capillary plexuses in adult (Figure 6K, L) and one-year-old (Figure 6K, M) mice. The number of I – D vertical sprouts was significantly lower in 3 – 6 month Jag1Ndr/Ndr retina compared to the Jag1+/+ retina (Figure 6L). In contrast, the number of vertical sprouts was similar between animals in one-year-old mice (Figure 6M). Nevertheless, vascular defects were present at both stages as noted by sparse vascular network in 3 – 6 months old Jag1Ndr/Ndr retina (Figure 6K, top panel) and discontinued intermediate capillary plexus in the one-year-old Jag1Ndr/Ndr retina (Figure 6K, bottom panel, white arrowheads).

The retina is a neural tissue, responsible for sight, in which retinal ganglion cells 119, the only afferent neurons, transmit signals from photoreceptors (rods and cones, the primary light-sensing cells), to the brain via the optic nerve. Approximately 90% of patients with Alagille syndrome display optic nerve anomalies such as optic disc drusen, which are hyaline-like calcified nodules 120. Retinal ganglion cells, whose cell bodies are located between the superficial and intermediate plexuses, are sensitive to hypoxia and to elevated levels of metabolites in the retina 121,122, suggesting retinal ganglion cells may be affected by the vascular defects identified here. To evaluate if the changes in retinal vasculature had neurological consequences, we investigated retinal ganglion cell axons by staining for neurofilament (NF). The retinal ganglion cells’ axons appeared healthy in both Jag1+/+ and Jag1Ndr/Ndr retinas at P10 (Figure 6N, white arrowheads label non-specific non-NF immunostaining of blood, due to use of mouse-on-mouse antibody), suggesting overall development of retinal ganglion cells was not severely disturbed. However, at P40 the retinal ganglion cells axons in Jag1Ndr/Ndr mice were thinner, tangled (Figure 6O) and covered 40% less area compared to Jag1+/+ mice (Figure 6P). In conclusion, our results show that the Jag1Ndr/Ndr adult vasculature aged prematurely, marked by retracting retinal capillaries resulting in reduced and later discontinued vascular network. The onset of vascular degeneration was associated with retinal ganglion cell degradation in Jag1Ndr/Ndr mice.

High blood pressure compromises vascular smooth muscle cell homeostasis in Jag1Ndr/Ndr mice

High blood pressure is one of the major risk factors contributing to cardiovascular diseases, subarachnoid hemorrhages and vessel tortuosity 108,123. Hypertension was reported in several patients with ALGS related to renal artery stenosis 24,124, or associated with visceral artery aneurysm 49, and may lead to complications during organ transplantation 125. Jag1Ndr/Ndr mice had significantly lower mean blood pressure (Figure 7A), ruling out high blood pressure as a cause of abnormal VSMCs and vessel tortuosity. To investigate whether increased blood pressure impacted on bleeding or vascular health, we treated Jag1Ndr/Ndr mice with Angiotensin II (AngII), a VSMC vasoconstrictor, for two weeks (experimental set up Figure 7B). Hypertension was defined as a systolic blood pressure above 140 mmHg 126 (Figure 7C, dotted line). Responsiveness to AngII was variable, we therefore selected AngII – treated animals with a minimum 20% increase in their mean blood pressure compared to baseline for further study (4 of 9 Jag1+/+ mice and 5 of 7 Jag1Ndr/Ndr mice, Supp Figure 3A, B). Of note, Jag1+/+ mice tended to lose weight during AngII treatment, while Jag1Ndr/Ndr mice increased in weight, resulting in a significant difference between these two groups (Supp Figure 3C, D).

Figure 7.
  • Download figure
  • Open in new tab
Figure 7. High blood pressure compromises vascular smooth muscle cell homeostasis in Jag1Ndr/Ndr mice.

(A) Mean blood pressure (BP) measurement in adult mice grouped by genotype and sex. (B) Experimental set up for Angiotensin II treatment. During week one, BP measurements were taken daily (blue tick marks) to establish the baseline levels and habituate the mice to measurements. At the beginning of week two, osmotic pumps with Angiotensin II or PBS control (red line) were implanted and BP was measured daily (blue tick marks). At the beginning of week four, mice were injected with Evans blue (EB) and organs were collected the next day. (C) Systolic BP levels before and during Angiotensin II treatment. The thin lines identify the same animal before and during treatment. The dotted line labels the cutoff for hypertension >140 mmHg systolic BP. These data are not tested for significance since animals were selected for analysis based on their response to Angiotensin, see also Supplementary Figure 3. (D) Measurement of Evans blue extracted from liver, kidney and heart. (E) Qualitative assessment of blood brain barrier permeability with Evans blue after Angiotensin II treatment, in which one Jag1Ndr/Ndr mouse of 5 displayed a macroscopically obvious Evans blue leakage. (F) Measurement of Evans blue extracted from the brain parenchyma, not including the hemisphere with the major leakage in (E). (G) Alpha smooth muscle actin (αSMA) coverage of retinal arterioles treated with control (PBS) or Angiotensin II. The green arrowhead marks a focal arterial narrowing in a Jag1Ndr/Ndr mouse. The blue arrowheads label an αSMA negative gap in an Angiotensin II-treated Jag1Ndr/Ndr mouse. Scale bar 10 μm. (H) Quantification of αSMA negative gaps in arterioles per retina. Statistical significance was tested with two-way ANOVA followed by multiple comparisons (A, D, F, H). Each dot represents one animal; graphs depict mean values ± standard deviation; p < 0.05 (*). AngII, Angiotensin II; αSMA, alpha smooth muscle actin; BP, blood pressure; EB, Evans blue; OD, optical density.

To evaluate if the increased blood pressure affected blood vessel permeability, we injected the mice with Evans blue. The amount of Evans blue extracted from internal organs was similar in AngII-treated Jag1+/+ and Jag1Ndr/Ndr mice and was similarly mildly increased compared to the untreated mice (Figure 7D). Macroscopic evaluation of the brain revealed that one of five AngII-treated Jag1Ndr/Ndr mice (a male) displayed Evans blue leakage outside of the intracranial vessels, suggesting a localized bleed in this animal (Figure 7E). However, the amount of Evans blue extracted from the brain tissue (excluding the hemisphere with a bleed) was similar in AngII-treated Jag1+/+ and Jag1Ndr/Ndr mice (Figure 7F). The amount of Evans blue extracted from brain tissue did not correlate with the change in blood pressure during AngII treatment for all animals tested (data not shown).

Finally, we examined whether increased blood pressure affected VSMCs. Jag1+/+ VSMCs were not affected by AngII treatment, by contrast arteriolar αSMA expressing VSMCs in Jag1Ndr/Ndr retina were absent in large patches (Figure 7G, blue arrowheads), resulting in a significant increase in αSMA negative gaps (Figure 7H), reminiscent of Notch3−/− mice at P30 16,127. In summary, our data show that VSMC homeostasis is compromised in AngII treated Jag1Ndr/Ndr mice, leading to gaps in VSMC coverage, and to intracranial vessel leakage in one of five Jag1Ndr/Ndr mice.

Vascular defects identified in Jag1Ndr/Ndr mice can be quantified non-invasively in patients with Alagille syndrome using retina fundus photography

Previous reports have shown that patients with ALGS have abnormal retinal vasculature 128–131, but the degree of tortuosity and patterning defects have not been quantified, nor compared to animal models, or CADASIL. We first analyzed retinal vasculature in a previously reported cohort of CADASIL patients 132,133. There were no significant differences in the numbers of arteriovenous crossings (Figure 8A, B), major arterioles or venules (Figure 8C, D) nor in arterial or venous tortuosity (Figure 8E, F) in patients with CADASIL compared to age-matched control patients. Arteriovenous crossings are more common in healthy human retina than in wild type mouse retina 134, therefore the observed artery-vein crossings in controls and CADASIL patients were expected. Venous tortuosity was mildly increased in some of the patients with CADASIL, but the degree of tortuosity did not correlate with sex (data not shown), nor with Fazekas score (a measure of white matter T2 hyperintense lesions used as a proxy for chronic small vessel ischemia, Supp Figure 4A). Interestingly venous tortuosity, but not arterial tortuosity (Supp Figure 4B, C), correlated positively with age in control patients (r = 0.6783, p= 0.0077, Supp Figure 4C), but not in patients with CADASIL (r = 0.1398, p=0.6337).

Figure 8.
  • Download figure
  • Open in new tab
Figure 8. Vascular defects identified in Jag1Ndr/Ndr mice can be quantified non-invasively in patients with Alagille syndrome using retina fundus photography.

(A) Retinograph examples from a healthy adult individual, a patient with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a healthy pediatric individual, a patient with Alagille syndrome (ALGS) and a patient with biliary atresia (BA, as a cholestatic control). Boxed regions magnify areas with arteriovenous crossing marked by black arrowheads. (B) Number of arteriovenous crossings per retina, per person, in Controls and CADASIL patients. (C, D) Quantification of (C) major arterioles and (D) venules at the border of the optic disc per person in Controls and CADASIL patients. (E, F) Measurement of (E) arterial and (F) venous tortuosity in Controls and CADASIL patients. (G) Number of arteriovenous crossings per retina in pediatric Controls, patients with ALGS, and patients with BA. (H, I) Quantification of (H) major arterioles and (I) venules at the border of the optic disc in pediatric Controls, patients with ALGS, and patients with BA. (J, K) Measurement of (J) arterial and (K) venous tortuosity in pediatric Controls, patients with ALGS, and patients with BA. Statistical significance was tested by unpaired Students t-test (B – F) or by one-way ANOVA followed by multiple comparisons (G – K). Each dot represents one individual; graphs depict mean values ± standard deviation; p < 0.05 (*), p < 0.01 (**). A, arteriole; ALGS, Alagille syndrome; AV, arteriovenous; BA, biliary atresia; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CTRL, control; V, venule.

Finally, we analyzed retinal fundus photographs from pediatric patients with ALGS, biliary atresia (BA, as cholestatic controls), and age-matched healthy control patients (previously reported in 128,135) (Figure 8A). Similar to the Jag1Ndr/Ndr mice (Figure 4A, B), arteriovenous crossings were significantly increased in patients with ALGS compared to the control group (Figure 8G). The number of major arterioles and venules were significantly lower in patients with ALGS compared to controls, but similar to patients with BA (Figure 8H, I), suggesting this phenotype (also present in Jag1Ndr/Ndr mice in Figure 4C, D) may be related to cholestasis. Finally, we examined vascular tortuosity, which was consistently increased in JagNdr/Ndr veins (Figure 4G, H). Arterial tortuosity was significantly increased in patients with ALGS compared to controls (Figure 8J), and venous tortuosity was increased in patients with ALGS compared to both patients with BA and healthy controls (Figure 8K). Interestingly, most patients with ALGS had either very high venous or arterial tortuosity, but rarely both (Supp Figure 4D). As expected in this small cohort, no patients in this group experienced intracranial bleeds, or bleeding events linked to known vascular abnormalities, and we could therefore not test whether vascular bleeding events correlated with vascular defects. One patient with ALGS had severe bleeding due to coagulopathy (patient f) that was secondary to the cholestatic liver disease. Three patients with BA had experienced gastrointestinal bleeding (Table 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2. Vascular events in patients with Alagille syndrome and biliary atresia, with vascular anomalies quantified in the retinographs in Figure 8.

(*) labels the age and vascular anomaly for which the blood values are provided. ALGS, Alagille syndrome; BA, biliary atresia; m, month.

Altogether, our data demonstrated that patients with ALGS had vascular abnormalities that could be visualized and quantified non-invasively. Specifically, patients with ALGS have more arteriovenous crossings, fewer major arterioles and venules, and increased vascular tortuosity. Increased venous tortuosity is highly penetrant in patients with ALGS (identified in five of six patients). Importantly, Jag1Ndr/Ndr mice recapitulate these phenotypes with fewer major blood vessels, more arteriovenous crossings, and increased vascular tortuosity.

Discussion

In this study, we describe multiple roles for Jag1 in patients and a mouse model for Alagille syndrome, in regulating blood vessel growth and homeostasis. We further identified risk factors that can lead to bleeds and demonstrated that vascular anomalies can be detected non-invasively in this pediatric populations using retinography. We investigated vascular anomalies in patients using a systematic literature search (150 patients with ALGS and vascular events), retrospective chart analysis (156 patients with ALGS), and retinography combined with retrospective chart analysis (6 patients with ALGS) and compared these findings to our investigation of vascular disease and bleeding in the ALGS mouse model. We showed that Jag1Ndr/Ndr mice recapitulate spontaneous bleeds, and exhibit arteriovenous crossings, reduction in blood vessel numbers, and an increase in blood vessel tortuosity. Importantly, several identified vascular events or phenotypes demonstrated a sex-bias.

Our data suggest dysfunctional JAG1 compromises blood vessel development and homeostasis, with consequences for both endothelial and vascular smooth muscle cells. Jag1Ndr/Ndr mice displayed many vascular developmental abnormalities such as delayed vascular outgrowth, reduced branching, abnormal tip cells and arteriovenous crossings. Previous studies indicate that many of the developmental defects observed here can be attributed to a role of JAG1 in endothelial cells 103,105. Developmental anomalies described in some patients with ALGS were agenesis of internal carotid artery 24,71 or aortic, renal and hepatic artery hypoplasia 25,28,29,33,58. Similarly, we and other groups have reported hypoplastic hepatic artery in Jag1 mutant mice 23,136, though this defect is probably secondary to bile duct agenesis 137.

Notch signaling is crucial for arterial specification during embryogenesis and arterial smooth muscle cell maintenance throughout life 138–141. Jag1Ndr/Ndr arterioles displayed delayed VSMC maturation and later poor VSMC coverage accompanied by accumulation of reactive astrocytes. The vast majority of vascular abnormalities in our literature review of patients with ALGS and vascular events, with sex data, were specific for arteries (196 events). Only twelve patients were reported with venous anomalies, which included cephalic vein stenosis 48, developmental venous anomaly, persistent falcine sinus (three patients) 10, abdominal wall venous dilation 73, displaced portal vein (three patients) 69, portal vein obstruction or stenosis 63,94 and arteriovenous malformations in liver and skin 81.

Retinal major arterioles and venules were tortuous in Jag1Ndr/Ndr mice and patients with ALGS. Surprisingly, although most reported anomalies in ALGS are related to arterioles, venules were more consistently tortuous than arterioles in both patients and the mouse model. Retinal vessel tortuosity is associated with hypertension, diabetes, genetic disorders, hypoxia related retinopathies, cerebral vessel disease, stroke and ischemic heart disease 142–145. Tortuosity of vessels can also arise as a consequence of dolichoectasia, vessel wall weakening leading to dilation and elongation of blood vessels (usually weakening of the tunica intima/endothelial cells, but sometimes also tunica media/vascular smooth muscle cells). Dolichoectasia is fairly common in Alagille syndrome: vascular neuroimaging of a cohort of 19 patients identified neurovascular defects in six patients, of which four were dolichoectasia (4/19 = 21%) 10. Previous reports qualitatively described retinal vasculature from patients with ALGS as tortuous or with abnormally angulated vessels 128,129,146. In our study, five of six patients with ALGS (83%) had tortuous venules (tortuosity above 5%), while patients with BA and control patients were consistently under 5%, suggesting venous vessel tortuosity as a suitable additional diagnostic feature. Abnormal retinal vessels may be correlated with other abnormal vessels in the body 147, and non-invasive retinal vascular imaging may thus serve as a screening method to investigate vascular compromise in patients with ALGS. We suggest that this could be studied in larger patient cohorts, for example via GALA (Global Alagille Syndrome Alliance), to determine whether retinal vascular defects correlate with, or are predictive of, cardiovascular accidents. The retinal vascular abnormalities found in patients with ALGS were absent in retinographs from patients with CADASIL, with the exception of arteriovenous nicking, which was only present in patients with CADASIL retinas (data not shown). Vascular changes in CADASIL patients have been identified using optical coherence tomography and optical coherence tomography angiography 132,133. Future studies in patients with ALGS should include high-resolution techniques as they may provide other new clinical biomarkers of vascular disease severity and prognosis for ALGS.

Our systematic literature review of 150 patients with ALGS and vascular events revealed unexpected sex differences. Female patients with ALGS were more often reported with intracranial bleeds, specifically subarachnoid hemorrhage (SAH). SAH was reported four-fold more for females than males with ALGS, while in the general population females are 1.3 times more likely to suffer from SAH 148. While reporting bias may affect the relative frequency of reported minor symptoms such as hematuria versus a more serious complication such as SAH, it is unlikely that reporting bias would lead to more publications of females with SAH, in particular since bleeding events in general were balanced between males and females. In line with this data in humans, Jag1Ndr/Ndr female mice exhibited more severely disrupted vasculature, with fewer major vessels. However, macroscopic bleeds were present in both male and female Jag1Ndr/Ndr mice in this study.

Ten patients in the literature review were reported with epidural/subdural/intracranial hematoma, often associated with minor head trauma and thin temporal bones 4,9. The skull was also thin with fused compact bones in Jag1Ndr/Ndr mice corroborating another risk factor in this mouse model. These data also further support previous reports for the role of Notch signaling in skeletal development and homeostasis 149.

Aging is a major risk factor contributing to the development of cardiovascular disease and is partly attributed to vessel wall changes leading to endothelial cell dysfunction 150 and loss of contractile VSMCs 151. Retinal vascular health was severely affected in adult (3 – 6 months old) Jag1Ndr/Ndr mice as shown by decreased vascular density and sparse VSMC coverage. Specifically, the number of branching points in the intermediate capillary plexus and the number of vertical sprouts in the adult Jag1Ndr/Ndr mice were similar to one-year-old wild type mice, demonstrating a premature aging-like phenotype. Reduced retinal vessel branching is also present in patients with ALGS 129 and could be seen in the retina fundus photographs from patients with ALGS (Figure 8), with reduced numbers of major arterioles and venules at the optic disc border. In the general population, ruptured intracranial aneurysms occur between 56 – 58 years of age 152, whereas the mean age for ruptured aneurysms in ALGS was 21.4 years 24,39,51,64,65,67,87,88. This may suggest that premature vascular aging in patients with ALGS leads to earlier onset of vascular bleeding and abnormalities. However, the presence of intracranial bleeding in newborns and infants (Table 1, Supplementary Table 1 85,90) also suggest a developmental cause of bleeding.

The VSMC pathology we describe for Jag1Ndr/Ndr mice (Figure 5, 7 and Supp Figure 2) is reminiscent of CADASIL, which may imply a risk for vascular dementia in patients with ALGS. Weak VSMC coverage in a ruptured intracranial aneurysm in patient with ALGS 115, further corroborates that VSMC pathology may be of concern in ALGS. VSMC health can be compromised by hypertension, indicating that patients’ blood pressure should be monitored carefully. Hypertension can lead to severe cardiovascular health complications like stroke, heart attack or SAH 123. Hypertension was reported in several patients with ALGS often related to renal artery stenosis 24,38,124 and associated with visceral artery aneurysm 49. We show that two weeks of hypertension in Jag1Ndr/Ndr mice caused degeneration of VSMCs, forming αSMA-negative gaps in the VSMC layer, while the wild type VSMCs were unaffected. Hence, hypertension might pose as an even greater risk factor for patients with ALGS compared to the general population. Our study has not directly examined VSMCs in patients, therefore future studies should aim to systematically determine whether VSMCs are compromised in patients with ALGS, whether this interacts with elevated blood pressure (as our results in mice suggest), and how this is similar or dissimilar to CADASIL.

Patients with ALGS exhibit several ocular abnormalities, of which the most common optic disc anomaly is optic disc drusen 130, which compresses adjacent ganglion cell axons and promotes retrograde axonal degeneration 153. Our data suggest that vascular pathology in the JAG1-mutant retina leads to local tissue hypoxia, negatively influencing the surrounding neurons, especially the retinal ganglion cells, which might explain the high incidence of optic disc drusen in ALGS patients. Fortunately, even though ALGS patients display many ocular abnormalities, complete vision loss is very rare 154. However, monitoring retinal vasculature and the development of optic disc drusen could also be investigated as a prognostic marker for vascular anomalies in the rest of the body.

Our data demonstrate that multiple risk factors likely contribute to bleeding in patients with ALGS, and that these pathologies are possible to study in the Jag1Ndr/Ndr mouse model (impact of sex, skull thinning and both EC and VSMC defects). Our data suggest that efforts should be made to identify and monitor patients that are at a greater risk of vascular disease (e.g. females with ALGS, aged 15 – 30 years old, who appear to have higher risk of SAH, or hypertensive patients with ALGS) and highlight the need for screening patients with ALGS for vascular and neurovascular changes. Future studies should aim to identify the patients at greatest risk of vascular disease in patients with ALGS, and devise treatments for vascular defects in this disease. Jag1Ndr/Ndr mice present a suitable tool for pre-clinical trials of vascular intervention therapies, which could draw inspiration from the field of CADASIL, also aiming at treating VSMC compromise.

Material and Methods

Systematic review search strategy

The Medline (Ovid), Embase and Web of Science Core Collection database were used for publication search. After the initial search, the duplicate publications were removed. During the screening process records that were not written in English, or publications that were impossible to access were removed. Publications that were included in the systematic review contained information about the patient sex and vascular event except for pulmonary artery stenosis, which is a hallmark of Alagille syndrome.

Search strategy for Medline:

Field labels: exp/ = exploded MeSH term; / = non exploded MeSH term; .ti,ab,kf. = title, abstract and author keywords; adjx = within x words, regardless of order; * = truncation of word for alternate endings

  1. Alagille Syndrome/

  2. (alagill* adj3 (syndrome* or watson or disease)).ti,ab,kf.

  3. (watson miller or arteriohepatic dysplasia or cardiovertebral syndrome or hepatic ductular hypoplasia or hepatofacioneurocardiovertebral or cholestasis with peripheral pulmonary stenosis or paucity of interlobular bile ducts or hepatic ductular hypoplasia).ti,ab,kf.

  4. or/1-3

  5. exp Cardiovascular System/ab, pa [Abnormalities, Pathology]

  6. exp Vascular Diseases/

  7. exp Hemorrhage/

  8. exp Vascular Malformations/

  9. (vascula* or cerebrovasc* or stroke* or aneurysm* or blood vessel* or artery or arteries or vein* or venous or moyamoya or moya moya or bleed* or hemorrhag*).ti,ab,kf.

  10. or/5-9

  11. 4 and 10

  12. remove duplicates from 11

Search strategy for Embase:

Field labels: /exp = exploded Emtree term; /de = non exploded Emtree term; ti,ab = title and abstract; NEAR/x = within x words, regardless of order; * = truncation of word for alternate endings

((‘alagille syndrome’/de) OR ((alagill* NEAR/3 (syndrome* OR watson OR disease)):ti,ab,kw) OR (‘watson miller’:ti,ab,kw OR ‘arteriohepatic dysplasia’:ti,ab,kw OR ‘cardiovertebral syndrome’:ti,ab,kw OR hepatofacioneurocardiovertebral:ti,ab,kw OR ‘cholestasis with peripheral pulmonary stenosis’:ti,ab,kw OR ‘paucity of interlobular bile ducts’:ti,ab,kw OR ‘hepatic ductular hypoplasia’:ti,ab,kw))

AND

((‘cardiovascular system’/exp AND (abnormal* OR patholog*)) OR (‘vascular disease’/exp) OR (‘bleeding’/exp) OR (vascula*:ti,ab,kw OR cerebrovasc*:ti,ab,kw OR stroke*:ti,ab,kw OR aneurysm*:ti,ab,kw OR ‘blood vessel*’:ti,ab,kw OR artery:ti,ab,kw OR arteries:ti,ab,kw OR vein*:ti,ab,kw OR venous:ti,ab,kw OR moyamoya:ti,ab,kw OR ‘moya moya’:ti,ab,kw OR bleed*:ti,ab,kw OR hemorrhag*:ti,ab,kw))

Search strategy for Web of Science Core Collection:

Field labels: TS/Topic = title, abstract, author keywords and Keywords Plus; NEAR/x = within x words, regardless of order; * = truncation of word for alternate endings

TS=(alagill* NEAR/3 (syndrome* OR watson OR disease)) OR TS=(“watson miller” OR “arteriohepatic dysplasia” OR “cardiovertebral syndrome” OR hepatofacioneurocardiovertebral OR “cholestasis with peripheral pulmonary stenosis” OR “paucity of interlobular bile ducts” OR “hepatic ductular hypoplasia”)

AND

TS=(vascula* OR cerebrovasc* OR stroke* OR aneurysm* OR “blood vessel*” OR artery OR arteries OR vein* OR venous OR moyamoya OR “moya moya” OR bleed* OR hemorrhag*)

Mouse maintenance and breeding

All animal experiments were performed in accordance with local rules and regulations and all animal experiments were approved by Stockholms Norra Djurförsöksetiska nämnd (Stockholm animal research ethics board, ethics approval numbers: N50/14, N61/16, N5253/19, N2987/20). The Nodder (Jag1+/Ndr colony) mice were maintained in a mixed C3H/C57bl6 genetic background as reported previously 23. In brief, Jag1+/Ndr mice are maintained in a C3H background (EMMA C3HeB/FeJ-Jag1Ndr/Ieg, EM: 13207) and outbred to C57bl6 for experiments. Jag1Ndr/Ndr mice are obtained from heterozygous crossings, and where possible littermates are used as controls. Because half of Jag1Ndr/Ndr mice die within 10 days of birth (this study and23), with further deaths at adult stages (23), the analysis of 3 mice at age one year entails the generation of at least 15 Jag1Ndr/Ndr mice and 45 wild types or heterozygous mice. Nodder mice were genotyped for the Ndr allele and sex by the Transnetyx® (USA) automated qPCR genotyping company. Mice were housed in cages with enrichment and maintained on a standard day-night (12 hour) cycle, with ad libitum access to food (standard chow SDS RM3 or SDS CRM, Special Diet Services) and water. Experiments generally include a mix of mice of both male and female sex. Experiments in which the results suggested there were sex differences were expanded with additional mice of each sex to determine whether sex differences were present.

Patient samples

Color photographs of the ocular fundii of patients with ALGS, BA and their age-matched controls were obtained after pupil dilatation using fundus cameras Canon EOS-1 Kodak Professional DCS 520C (Canon, Rochester, New York, USA) or Canon CRDG non-mydriatic retinal camera (Canon, Tokyo, Japan). Only correctly focused photographs either from eyes with both the macula and the optic disc visible, or from eyes with the optic disc in the center, were used for the analysis. Data collection and analysis was performed under the 335/00, and 2019-00202 ethical permits approved by Regional ethics review board in Stockholm. The retina fundus photographs were analyzed from seven healthy pediatric control patients (median age 8 years, range 7 – 8 years; 1 male, 6 females), six patients with ALGS (median age 7.5 years, range 2 – 11 years; 1 male, 5 females), four patients with BA (median age 10.5 years, range 8 – 16 years; 1 male, 3 females). The patients included in this study and/or their guardians gave written informed consent, and were previously reported in part 128,135.

Color fundus photography of patients with CADASIL and their aged-matched controls was performed using Visucam (Carl Zeiss Meditech, Germany). The data collection and analysis were approved by the IRB of the Ärztekammer Westfalen-Lippe and University of Münster (2015-402-f-S). All subjects gave written informed consent. Data from these patients have been published in part in previous studies 132,133. Fourteen healthy adult control patients (median age 48 year, range 23 – 61 years; 5 males, 9 females) and 14 patients with CADASIL (median age 51 year, 6 males, 8 females).

Retrospective chart analysis for patients at Children’s Hospital of Fudan University was performed in 2018, under ethical permit No (2015) 178, approved by the ethical board of Children’s Hospital of Fudan University. Retrospective chart analysis did not require informed consent.

The medical history from patients with ALGS or BA, whose retina fundus photographs were analyzed here, follows the decision 2017/1394-31 by the Regional ethics review board in Stockholm. Permission was given to retrospectively collect data from charts of patients with chronic cholestatic disease without additional consent from patients.

Immunofluorescence staining of retina

Eyes were fixed with 3.8% Formaldehyde solution (Sigma-Aldrich, cat. #F1635) overnight and whole retinas were dissected out, blocked and permeabilized in phosphate buffered saline (PBS) containing 1% Bovine serum albumin (Sigma-Aldrich, cat. # A2153) with 0.3% TritonX-100 (Sigma-Aldrich, cat. #T8787). Primary and secondary antibodies were diluted in blocking solution. PBS : blocking solution (1:1) was used as a washing buffer. Each step was performed at 4°C, overnight. Retinas were flat-mounted in Vectashield (cat. no. H-1000, Vector Laboratories). Primary antibodies used: rat anti-mouse CD31 (cat. #553370, BD Biosciences, 1:100), rabbit anti-ERG (cat. #ab92513, Abcam, 1:200), goat-anti DLL4 (cat. #AF1389, RnD systems, dilution 1:200), goat anti-CD13 (cat. #AF2335, RnD Systems), goat anti-Jagged1 (cat. #J4127, Sigma-Aldrich, 1:500), mouse anti-human α-smooth muscle actin (Cy3 conjugated, cat. #C6198, Sigma Aldrich, 1:500; FITC conjugated, cat. #F3777, Sigma Aldrich, 1:500), rabbit anti-HISTONE H3 (phospho S10) (cat. #ab5176, Abcam, 1:500), rabbit anti-NOTCH3 (cat. #Ab23426, Abcam, 1:500), mouse anti-GFAP (Cy3 conjugated, cat. # MAB3402C3, Sigma-Aldrich, 1:500), rabbit anti-Cleaved CASPASE3 (cat. #9661 (D175), Cell Signaling, 1:700), rabbit anti-COLLAGEN type IV (cat. # AB756P, Merck Millipore, 1:500), mouse anti-Neurofilament (cat. #RT97, DSHB, 1:200) nuclei were labeled with DAPI (cat. #D9542, Sigma Aldrich, 1:1000). Images were captured using LSM 510 META or LSM 880 (Carl Zeiss AG) microscopes and processed in Image J (NIH), and/or Adobe image suite software (Adobe Inc). Any image modifications were applied identically to images being compared.

Quantitative analysis of the retinal vasculature

Vascular outgrowth analysis

The distance from the optic nerve to the periphery of a retina was measured in ImageJ (NIH) using the straight line tool. Distance was measured on tile-scanned images (10x objective) of whole retina. 6 measurements, regularly radially spaced at approximately 60 degree intervals, were performed per retina from 4 Jag1+/+ and 4 Jag1Ndr/Ndr animals at P5.

Tip cells and filopodia analysis

Tip cells were defined as CD31+Erg+ cells with extended filopodia at the vascular front. The number of tips per tip cell was quantified as the number of tips with filopodia bundles (single membrane protrusions coming out of a tip cell) extending in a single direction, divided by the number of tip cells. Filopodia was defined as single hair-like membrane protrusions extending from a tip cell. The number of filopodia was then divided either by the number of tip cells or by the number of tips. All quantifications were counted manually in Image J, in 40x images, 4 images per animal, in 5 Jag1+/+ and 6 Jag1Ndr/Ndr mice at P5.

Quantification of vascular density, branching point and number of ERG+ endothelial cells

The number of branching points per field (40x objective) was manually quantified in the middle of the outgrowing vascular plexus (at P10, P15, adult and 1 year halfway between an arteriole and venule). The quantification of branching points was performed in 3-6 images per animal, in 5 Jag1+/+ and 4 Jag1Ndr/Ndr mice at P5, 3 Jag1+/+ and 3 Jag1Ndr/Ndr mice at P10, P15, and 5 Jag1+/+ and 5 Jag1Ndr/Ndr adult mice (3 – 6 months) or aged animals (1 year). In each 40x field the number of ERG+ nuclei were manually quantified in 3 images per animal, in 5 Jag1+/+ and 5 Jag1Ndr/Ndr mice at P5, in 5 images per animal, and in 3 Jag1+/+ and 3 Jag1Ndr/Ndr mice at P10, and P15. In the same field, the CD31+ vascular length was manually measured using the free hand tool in ImageJ. The number of ERG+ endothelial cells was divided by vascular length.

Phosphorylated Histone3 proliferation analysis

Whole retina tile-scans (objective 10x) were taken from 4 Jag1+/+ and 4 Jag1Ndr/Ndr mice at P5, and 3 Jag1+/+ and 3 Jag1Ndr/Ndr mice at P10 and P15. Phospho-Histone H3+ (PH3+) CD31+ cells were manually counted in a field within a 45° wedge originating at the optic nerve, in zones of radius 200 μm, in 12 zones altogether (Supp Figure 1D). The average number of PH3+CD31+ per zone was normalized to the zone area (μm2) and multiplied by 100 (per 100 μm2 area).

Vessel diameter analysis

Vessel diameter was measured at a distance of 220 μm and 460 μm from the optic nerve in ImageJ for all major arterioles and venules in 3 Jag1+/+ and 3 Jag1Ndr/Ndr mice at 1 year. The vessel diameter from the two measurements was averaged.

Cleaved Caspase 3

The number of cleaved caspase3 (Cl. CASP3) positive cells was quantified manually along arterioles. The arterioles were imaged in confocal z-stacks and inspected for cl. CASP3+ cells throughout the stacks. The number of branching points per image (field), the number of cl. CASP3+ cells at a branching point and the number of cl. CASP3+ outside of a branching point were manually quantified. The number of Cl. CASP3 positive cells was addressed in aged mice (>1 year old) in 7 – 13 stacks per mouse, in 5 Jag1+/+ and 6 Jag1Ndr/Ndr mice.

Arterial and venous segregation

In murine retinas, the number of major arterioles and venules originating at the optic nerve, and the number of arteriovenous crossings, were quantified in whole mount retinas stained for CD31 and αSMA. Six male and 6 female Jag1+/+ and 4 male and 4 female Jag1Ndr/Ndr adults were included for quantification of arterioles and venules. Arteriole/arteriole and arteriole/venule crossings were counted and grouped together. No venule/venule crossings were observed. Altogether 6 male and 5 female Jag1+/+ mice and 7 male and 5 female Jag1Ndr/Ndr mice were included for quantification of aberrant crossings in adult mice (3 – 6 months).

In human retinas, the number of major arterioles and venules were quantified at the border of the optic nerve head from fundus photographs in which the optic nerve head was the center of the image. The venules were recognized by their darker color. The number of arteriovenous crossings was counted. No distinction was made between arteriovenous crossing and nicking. Patients with ALGS – 3, BA – 4, pediatric control – 6, CADASIL – 14, adult control – 14.

Vessel tortuosity

Blood vessel tortuosity was addressed by manually tracing the curve length of major arterioles and venules from the optic nerve towards the periphery in murine whole retina (20x objective) or human retina fundus photographs, in Adobe Illustrator. In murine retinas, only the main branches were traced for analysis. In human retinas, only branches that extended to the periphery (edge of the image) were included for analysis. The chord length was manually measured as a straight line connecting the start point to the end point of a vessel. The tortuosity was calculated by dividing the vessel curved length by its chord length. The result was transferred into percentage and subtracted by 100 to yield the % increase in tortuosity compared to straight (0% would be a perfectly straight blood vessel). The analysis was performed on whole retinas from one eye from 4 Jag1+/+ and 4 Jag1Ndr/Ndr P30 mice, 3 Jag1+/+ and 3 Jag1Ndr/Ndr one-year-old mice and all the patients included in the study (both eyes).

Vertical sprouting analysis

To address the overall number of sprouts connecting SCP to ICP and DCP to ICP a single image from a z-stack halfway between SCP to ICP and DCP to ICP was analyzed. A sprout in this image appears as a single dot. One Z-stack image (40x objective) taken in the middle of a retina between arteriole and venule was analyzed per animal. 5 Jag1+/+ and 5 Jag1Ndr/Ndr adult mice (3 – 6 months) and 9 Jag1+/+ and 8 Jag1Ndr/Ndr aged animals (one year) were used.

Superficial and intermediate capillary plexus integrity

The number of SCP and ICP branching points was quantified in z-projected images (ImageJ) of the SCP or ICP (40x objective) taken in the middle of the retina between arteriole and venule. Four images from 6 Jag1+/+ and 7 Jag1Ndr/Ndr adult animals and 2 - 5 images from 6 Jag1+/+ and 5 Jag1Ndr/Ndr one-year-old animals were analyzed. In the same field, the CD31+ vascular length was measured by free hand tool in ImageJ. In the same image, in 3 Jag1+/+ and 3 Jag1Ndr/Ndr adult animals (3 – 6 months), the length of empty CollagenIV sleeves was measured using the free hand tool in ImageJ.

Neurofilament quantification

Neurofilament coverage was quantified in ImageJ and calculated as % of area covered by neurofilaments of the total area (100%). Neurofilament area was measured using the following script in ImageJ:

run(“Measure”);

run(“8-bit”);

run(“Median...”, “radius=2”);

setAutoThreshold(“Mean dark”);

//run(“Threshold...”);

//setThreshold(6, 255);

setOption(“BlackBackground”, false);

run(“Convert to Mask”);

run(“Watershed”);

run(“Analyze Particles...”);

Total area was measured by Measure (ctrl+M command)

The measurement was performed on 2-4 images from 3 Jag1+/+ and 4 Jag1Ndr/Ndr P40 animals.

Fluorescence intensity

The blood vessel of interest was outlined using the lasso tool. The intensity was assessed by the histogram function for individual channels in Adobe Photoshop.

GFAP intensity was quantified in adults from 3 images from 4 Jag1+/+ and 4 Jag1Ndr/Ndr mice.

JAG1 intensity was quantified in adults from 4 images from 4 Jag1+/+ and 4 Jag1Ndr/Ndr mice.

NOTCH3 intensity was quantified in adults from 4 images from 4 Jag1+/+ and 4 Jag1Ndr/Ndr mice.

ASMA gaps

The number of gaps in αSMA coverage was quantified manually. An αSMA gap was considered a gap between two vascular smooth muscle cells that is greater than one cell width (~ >10 μm). The total number of gaps per retina was counted. The number of gaps was quantified in 4 Jag1+/+, 3 Jag1Ndr/Ndr, 4 Jag1+/+ treated with Angiotensin II and 5 Jag1Ndr/Ndr treated with Angiotensin II.

Whole organ hemorrhage analysis and imaging

Freshly dissected brains and retinas were inspected for the presence of hemorrhages under a stereomicroscope Stemi 305 (Carl Zeiss Microscopy). Whole organs or tissue images were taken with a stereomicroscope Stemi 305 (Carl Zeiss Microscopy) combined with Canon camera (Cannon, PowerShot S3 IS). The background around the tissue was covered by a solid black color in Adobe Photoshop for esthetic purposes.

Image processing

Capillary plexus visualization was accomplished by splitting z-stack images into 3 equally sized z-stacks per animal, color coding each plexus and merging the 3 images. Due to different sizes of Jag1+/+ and Jag1Ndr/Ndr retinas, stack sizes were different among animals. Images at P15 and 1 year (Figure 1B, Sup Figure 2A) were further processed in ImageJ by median filter (radius = 1).

Retina whole vasculature side images were further processed in Volocity in which high opacity and noise reduction filters were included.

Liver resin casting

Adult liver portal vein vasculature was injected with synthetic resin MICROFIL® and scanned with micro computed tomography as previously described 102.

Micro CT analysis of ruptures

Following the micro-CT measurements, the reconstructed data was imported in VG Studio MAX software (Volume Graphics GmbH, https://www.volumegraphics.com). The Microfil-filled structures were separated from the background by global thresholding creating a main region of interest (ROI), then the areas of Microfil leaked from ruptured vessels were manually selected into separate ROIs. The volume of each ROI of leaked Microfil was calculated by the software. The analysis was performed in 4 Jag1+/+, 4 Jag1Ndr/Ndr samples (analyses of portal vein and biliary architecture, but not vascular leakage data, for 3 Jag1+/+ and 3 Jag1Ndr/Ndr samples of these casts were previously published in 102).

Skull micro computed tomography

Micro-computed tomography (microCT) was performed on 7 and 8 month old skulls (3 Jag1+/+ and 3 Jag1Ndr/Ndr mice, all males) using a MicroCT50 (Scanco Medical), 55kVp, 109μA, 6W at 20μm voxel size, with a 500 ms integration time and a 20.5 mm field of view.

Skull thickness and volume analysis

The skull thickness and volume analyses were conducted in VG Studio MAX 3.4 (Volume Graphics GmbH, Germany). A sample was registered within the coordinate system, and the skull surface was determined, including the jaws. The volume was calculated by multiplying the number of voxels of a given surface by the volume of one voxel. The skull thickness was measured by utilizing a ray, searching for the opposite surface for each point on the skull surface. The resulting thickness map depicts the shortest distances between the inner and outer surface. The thickness and volume of the skulls were measured in two different ways, one of the whole skull thickness and one taking into account the trabeculation of the spongy bone. The spongy bone segmentation was conducted using the VGEasyPore module. The analysis was performed in 3 Jag1+/+, 3 Jag1Ndr/Ndr adult samples.

Skull length

The skull length was measured in Image J using the straight line tool. The length was measured from the occipital bone to the nasal bone from a dorsal view. The measurement was performed for 3 Jag1+/+, 3 Jag1Ndr/Ndr skulls.

Vessel permeability assay

Mice were injected with 200 μl 0.5% Evans blue (cat. #E2153, Sigma-Aldrich) via the tail vein. The dye was allowed to circulate for 17 hours. Mice were anesthetized by CO2 inhalation and transcardially perfused with Hanks buffered salt solution (HBSS), at a perfusion rate of 5 ml/min for 3 min. Internal organs were dissected out, weighed, and placed in Formamide solution (cat. # 15515-026, Invitrogen) for 17 hours at 56°C. Formamide solution containing Evans blue extracted from the organs was measured for absorbance at 610 nm in a VersaMax™ microplate reader (Molecular Devices Versa Max microplate reader). The amount of Evans blue measured was divided by the organ weight. Brain vasculature was inspected under the stereomicroscope Stemi 305 (Carl Zeiss Microscopy) and photographed with a camera (Cannon, PowerShot S3 IS).

Blood pressure measurements

Blood pressure was measured using the CODA® High Throughput (Kent Scientific) tail cuff system. The animals were awake, on a heating pad, and in a restraining device, during the experiment. The animals were accustomed to the tail cuff for 5 min before data recording. The tail temperature was assessed between 32 – 34°C. The systolic, diastolic and mean blood pressure were recorded. The mean baseline blood pressure was calculated as an average from 5 recordings on 5 days. In the Angiotensin II experiment, the mean blood pressure is the average of nine recordings. The increase in blood pressure was calculated by comparing the average mean blood pressure before Angiotensin II treatment (100%) and during two weeks of Angiotensin II treatment.

Angiotensin II treatment

Mice were treated with Angiotensin II (cat. #A6402, Sigma-Aldrich) for two weeks. Angiotensin II was delivered via osmotic mini pumps (Alzet®, 2002 model) and the infusion rate was 0.025 μg/g/h. The animals were anesthetized by Isoflurane inhalation (~2%) and IP injected with 200 μl Rimadyl (0.5 mg/ml) prior to the surgery to relieve pain. The osmotic mini pumps were implanted subcutaneously and the incision was sealed with surgical glue. Animals in the experiment were weighed daily and the blood pressure was measured to verify the effect of Angiotensin II treatment. 2 of 11 Jag1+/+ mice, and 1 of 8 Jag1Ndr/Ndr mice demonstrated a strong reaction to Angiotensin II treatment (weight loss > 20% and piloerection) and had to be sacrificed. 5 Jag1+/+ and 2 Jag1Ndr/Ndr mice had weak or no response to Angiotensin II (no blood pressure increase) and were therefore excluded from the analysis. Animals were given extra “porridge” during the treatment to avoid dehydration. Control animals were implanted with mini-pumps loaded with Dulbecco’s phosphate buffer saline (DPBS), in total 4 Jag1+/+ and 5 Jag1Ndr/Ndr mice.

Body weight

Jag1+/+ and Jag1Ndr/Ndr body weight was recorded from the first day of blood pressure measurement and throughout the Angiotensin II treatment. In the body weight graph, day 0 is body weight before the Angiotensin II treatment and day 1 is body weight from the first day of Angiotensin II treatment. Body weight change is calculated by comparing the body weight from the last day of Angiotensin II treatment to the body weight from the first day of AngII treatment (100%).

Thrombin-Antithrombin ELISA

Thrombin-Antithrombin (TAT) complexes were measured by ELISA using a commercial kit (cat. #ab137994, Abcam). The assay was performed according to manufacturer’s instructions. The chromogen substrate was incubated for 20 min and the absorbance was read at 450 nm using VersaMax™ microplate reader. The TAT ELISA was performed on P10 plasma (4 Jag1+/+ and 4 Jag1Ndr/Ndr mice).

Plasma collection

Blood from P10 mice was collected from the trunk after decapitation. To obtain blood plasma the blood was mixed with 10 μl of Heparin (LEO Pharma) and kept cold throughout handling. Afterwards, the blood-Heparin mix was centrifuged at 3000 g for 15 mins at 4°C. Plasma was carefully removed from the top layer, placed in a new tube, and frozen (−20°C short term (max 2 weeks), −80°C long term storage).

Liver enzyme analysis

Liver enzymes (including total bilirubin) were analyzed from blood plasma of P10 mice diluted six times with DPBS. The blood plasma was tested using mammalian liver profile (Abaxis, PN 500-1040) and VetScan2 system (Abaxis Inc).

Survival analysis

Newborn pups were observed and counted daily during the first 10 days after birth. The number of deceased pups was noted. The pups were biopsied, tattooed and genotyped. 23 Jag1+/+ and 16 Jag1Ndr/Ndr were included in the analysis, 6 Jag1Ndr/Ndr pups died during the first 10 days.

Electron microscopy

Animals were anesthetized and transcardially perfused with HBSS and electron microscopy fixative (2% formaldehyde, 2.5% glutaraldehyde and 0.02% sodium azide in 0.05 M sodium cacodylate buffer, pH 7.2) as previously described 140. For retina and heart analysis 6 Jag1+/+ and 6 Jag1Ndr/Ndr mice were used. Images were further processed in Adobe Photoshop to pseudocolor cell types.

Quantitative real time qPCR

RNA was isolated from adult whole retinas of 3 Jag1+/+ and 3 Jag1Ndr/Ndr mice. mRNA was extracted using the RNeasy Mini Kit (QIAGEN, cat. #74104), including on-column DNase I digestion (QIAGEN, cat. #79254). Complementary DNA was synthesized from 1 μg total RNA using the Thermo Scientific™ Maxima™ First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific, cat. #K1641) according to the manufacturer instructions. Quantitative real-time PCR (qPCR) was performed as described 155. Primers used for qPCR are listed below. mRNA levels are normalized to the average housekeeping RNA levels of 18S and β-actin.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Statistical analysis

Statistical analyses of differences between Jag1+/+ and Jag1Ndr/Ndr animals was evaluated using two-sided unequal variance t test or Mann-Whitney test. When more than 2 conditions were compared, a one-way of two-way ANOVA combined with Sidak’s multiple comparisons test was used, as appropriate and as described in figure legends. Pearson correlation was used for correlation analysis. P value was considered as statistically significant if p<0.05 (p<0.05 = *, p<0.01 = **, p<0.0001 = ***).

Author contributions

SH conceptualization, data curation, formal analysis, investigation, visualization and writing of original draft. NVH investigation and writing – review and editing. JL investigation, formal analysis and writing review and editing. NH investigation, validation and visualization. EV investigation, validation and visualization. TZ conceptualization and project administration. FD investigation. MK investigation and writing – review and editing. JS investigation. LL investigation. MS investigation. BRJ investigation. MH investigation. VB funding acquisition and writing – review and editing. UL funding acquisition and writing – review and editing.

AJ funding acquisition, investigation. JSW investigation, resources. FA resources and writing – review and editing. KTF resources and writing – review and editing. BF investigation, resources and writing – review and editing. JK funding acquisition, project administration, supervision and writing – review and editing. ERA conceptualization, funding acquisition, project administration, supervision and writing – original draft.

Grant support

ERA and members of Andersson lab were supported by a Center of Innovative Medicine (CIMED) Grant, the Ragnar Söderberg Foundation (Swedish Foundations’ Starting Grant), the Swedish Research Council, the EASL Daniel Alagille Award, the Heart and Lung Foundation, KI Funding and Alex and Eva Wallström Foundation.

SH was supported by Wera Ekströms Stiftelse and a grant for KI-MU exchange, and grants in ERA lab. SH was supported by “KI-MU” program (CZ.1.07/2.3.00/20.0180) co-financed from European Social Fund and the state budget of the Czech Republic. Work in VB laboratory is supported by Czech Science Foundation project Expro (GX19-28347X).

JK and members of the Kaiser group were supported by CzechNanoLab Research Infrastructure supported by MEYS CR (LM2018110).

Supplementary Figures

Supplementary Figure 1.
  • Download figure
  • Open in new tab
Supplementary Figure 1. Delayed retinal vascular outgrowth and remodeling in Jag1Ndr/Ndr mice.

(A) Capillary extension into deep capillary plexus at postnatal day 10 (P10). Scale bars 100 μm. (B) Overview of three pseudocolored retinal capillary layers at P15. Scale bars 50 μm. (C) Quantification at P5 of number of filopodia per tip (top panel) and filopodia per tip cell (bottom panel). (D) Schematic representing radial zone delineation for quantification of phosphorylated histone 3 (PH3) positive endothelial cells. The CD31+PH3+ cells were counted in 200 μm zones in a 45° wedge (4 wedges per retina). (E) Immunofluorescence of PH3+ proliferating CD31+ endothelial cells at P5. The dotted line labels the edge of the vascular front. Quantification of the number of proliferating cells per radial zone, normalized to area size at P5. Scale bars 50 μm. (F, G) Number of proliferating endothelial cells per radial zone, normalized to area size at (F) P10 and (G) P15. Scale bars 100 μm. Statistical significance was tested using unpaired Students t-test (C) or two-way ANOVA followed by multiple comparisons (E – G). In C, each dot represents one animal; graphs depict mean values ± standard deviation, in E each dot represents the mean value ± standard deviation from 4 animals per genotype in F and G each dot represents the mean value from 3 animals per genotype; p < 0.05 (*).

Supplementary Figure 2.
  • Download figure
  • Open in new tab
Supplementary Figure 2. Jag1Ndr/Ndr mice display CADASIL-like sparse vascular smooth muscle cell coverage of arteries with an increase in artery-associated reactive astrocytes.

(A) Pericyte coverage of blood vessels stained for CD13 was not reduced in Jag1Ndr/Ndr mice. Scale bars 100 μm. (B) Transmission electron microscopy of coronary arteries of adult mice. Vascular smooth muscle cells (SMC) are pseudo colored in magenta and endothelial cells (ECs) in green. White arrowheads label SMC edges and the distances between SMCs. Green arrowhead marks the tight junctions. Scale bars 2 μm. (C) JAG1 and NOTCH3 expression in retinal arterioles. Scale bars 10 μm. (D) JAG1 mean intensity was significantly increased in Jag1Ndr/Ndr mice. (E) NOTCH3 mean intensity on arterioles and mRNA levels (F) in whole retina lysates. (G – J) GFAP+ astrocytes are more prevalent around Jag1Ndr/Ndr (G) arterioles (H) but there was no difference around veins. White arrowheads label reactive astrocytes. Scale bars 20 μm. (I, J) GFAP mean intensity on retinal (I) arterioles and (J) venules. Statistical significance was tested using unpaired Students t-test (D – F, I, J). Each dot represents one animal; graphs depict mean values ± standard deviation; p < 0.05 (*), p < 0.01 (**). A, arteriole; EC, endothelial cell; SMC, smooth muscle cell; V, venule.

Supplementary Figure 3.
  • Download figure
  • Open in new tab
Supplementary Figure 3. Animal response to Angiotensin II treatment, and selection of responsive animals for analysis.

(A) Average mean blood pressure during Angiotensin II treatment of all animals. (B)Change in the mean blood pressure during Angiotensin II treatment compared to average before the treatment. Mice with no change in blood pressure, or a decrease in blood pressure, were set to zero for this analysis. Green arrows and boxes demarcate the animals that responded with a minimum 20% increase in mean blood pressure and were used in further analysis (Figure 7). (C) Body weight of all mice during treatment with Angiotensin II. In total 9 Jag1+/+ and 7 Jag1Ndr/Ndr mice. (D) Change in body weight at day 12 of Angiotensin II treatment compared to day 0 (before Angiotensin II treatment). Statistical significance was tested using unpaired Students t-test (B, D) or two way ANOVA (A, C). In A, B and D, each dot represents one animal; graphs depict mean values ± standard deviation; in C each dot represents the mean values from 9 and 7 mice as described above ± standard deviation; p < 0.05 (*). AngII, Angiotensin II.

Supplementary Figure 4.
  • Download figure
  • Open in new tab
Supplementary Figure 4. Correlation of retinographs vascular abnormalities with different factors.

(A) Lack of correlation for arteriolar and venous tortuosity and arteriovenous crossing to Fazekas scores for CADASIL and control patients. The data for each parameter are normalized to the average value of each parameter corresponding to Fazekas score 1 value. (B) Correlation analysis between arterial tortuosity and age for CADASIL and age-matched control patients. (C) Correlation analysis between venous tortuosity and age for CADASIL and age-matched control patients. (D) Correlation analysis between arterial and venous tortuosity in patients with Alagille syndrome and pediatric controls. Statistical significance was tested by Pearson correlation (A – D). Each dot represents one individual; graphs depict mean values ± standard deviation. A, arteriole; ALGS, Alagille syndrome; AV, arteriovenous; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; V, venule.

Supplementary Table

View this table:
  • View inline
  • View popup
Supplementary table 1.

Overview of 150 patients with Alagille syndrome identified in the systematic literature review. Table describes patients’ age, sex, structural anomaly and functional event. F, female; M, male; m, month; MAPCA, major aortopulmonary collateral arteries; y, years.

Acknowledgments

We would like to thank Soniya Savant for her input regarding vascular phenotypes and single cell sequencing library preparation (not included in manuscript). We would like to thank Katarina Tiklova for her advice and help with single cell sequencing library preparation and FACS sorting (not included in manuscript). We thank Liqun He and Christer Betsholtz for their help with single cell analysis (not included in manuscript). Further, we would like to thank Tomasz Krzywkowski and Mats Nilsson for their efforts to help us adapt retina padlock probe in situ hybridization to retina (not included in manuscript). We would also like to thank the Rickard Sandberg group especially Gösta Winberg for providing us with Tn5 enzyme and other buffers for SmartSeq2 libraries and their input on the library quality (not included in manuscript). We would like to thank SciLife for their help with single cell RNA sequencing and bioinformatic analysis (not included in manuscript). The monoclonal antibody NF-RT97 developed by Wood, J. obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.

Abbreviations

A
artery/arteriole
ALGS
Alagille syndrome
AngII
Angiotensin II
ASMA
alpha smooth muscle cell actin
AV
arteriovenous
BA
biliary atresia
BP
blood pressure
cCasp3
cleaved Caspase 3
CADASIL
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CD31
PECAM-1
ColIV
Collagen IV
CTRL
control
D
deep
DCP
deep capillary plexus
Dll4
Delta-like 4
EB
Evans blue
EC
endothelial cell
Erg
ETS-related gene
g
gram
GI
gastrointestinal
GFAP
Glial fibrillary acidic protein
I
intermediate
Hg
mercury
IC
intracranial
ICP
intermediate capillary plexus
Jag1
Jagged1
mm
millimeter
n
number of biological replicates
Ndr
Nodder
NF
neurofilament
ns
not significant
OD
optical density
P
postnatal day
PAS
pulmonary artery stenosis
PH3
phospho-histone 3
S
superficial
SCP
superficial capillary plexus
TAT
thrombin-antithrombin
V
vein/venule
VSMC
vascular smooth muscle cell
mCT
micro computed tomography
mm
micrometer

References

  1. 1.↵
    Alagille D, Odièvre M, Gautier M, et al. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr 1975;86:63–71.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.
    Gilbert MA, Bauer RC, Rajagopalan R, et al. Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum Mutat 2019:1–24.
  3. 3.↵
    Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999;29:822–829.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Hoffenberg EJ, Narkewicz MR, Sondheimer JM, et al. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995;127:220–4.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.
    Lykavieris P, Crosnier C, Trichet C, et al. Bleeding tendency in children with Alagille syndrome. Pediatrics 2003;111:167–70.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Kamath BM, Spinner NB, Emerick KM, et al. Vascular Anomalies in Alagille Syndrome: A Significant Cause of Morbidity and Mortality. Circulation 2004;109:1354–1358.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Quiros-Tejeira RE, Ament ME, Heyman MB, et al. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr 1999;29:431–437.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Kazi R, Fakhoury J, Beck R. A Case of Recurrent Intracranial Bleeds in the Setting of Alagille Syndrome. Pediatrics 2018;142.
  9. 9.↵
    Petaros A, Miletic D, Stifter S, et al. Alagille syndrome case report: implications for forensic pathology and anthropology. Int J Legal Med 2015;129:543–549.
    OpenUrl
  10. 10.↵
    Carpenter CD, Linscott LL, Leach JL, et al. Spectrum of cerebral arterial and venous abnormalities in Alagille syndrome. Pediatr Radiol 2018;48:602–608.
    OpenUrl
  11. 11.↵
    Li L, Krantz ID, Deng Y, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997;16:243–51.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.
    Oda T, Elkahloun AG, Pike BL, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997;16:235–242.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    McDaniell R, Warthen DM, Sanchez-Lara PA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2006;79:169–73.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Benedito R, Hellström M. Notch as a hub for signaling in angiogenesis. Exp Cell Res 2013;319:1281–1288.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Phng LK, Gerhardt H. Angiogenesis: A Team Effort Coordinated by Notch. Dev Cell 2009;16:196–208.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Henshall TL, Keller A, He L, et al. Notch3 is necessary for blood vessel integrity in the central nervous system. Arterioscler Thromb Vasc Biol 2015;35:409–420.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann N Y Acad Sci 1997;826:213–217.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Stittrich AB, Lehman A, Bodian DL, et al. Mutations in NOTCH1 cause Adams-Oliver syndrome. Am J Hum Genet 2014;95:275–284.
    OpenUrlCrossRefPubMed
  19. 19.
    Meester JAN, Southgate L, Stittrich AB, et al. Heterozygous Loss-of-Function Mutations in DLL4 Cause Adams-Oliver Syndrome. Am J Hum Genet 2015;97:475–482.
    OpenUrlCrossRefPubMed
  20. 20.
    Hassed SJ, Wiley GB, Wang S, et al. RBPJ mutations identified in two families affected by Adams-Oliver syndrome. Am J Hum Genet 2012;91:391–395.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Southgate L, Sukalo M, Karountzos AS V, et al. Haploinsufficiency of the NOTCH1 Receptor as a Cause of Adams-Oliver Syndrome with Variable Cardiac Anomalies. Circ Cardiovasc Genet 2015;8:572–581.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Mašek J, Andersson ER. The developmental biology of genetic Notch disorders. Development 2017;144:1743–1763.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Andersson ER, Chivukula I V, Hankeova S, et al. Mouse Model of Alagille Syndrome and Mechanisms of Jagged1 Missense Mutations. Gastroenterology 2018;154:1080–1095.
    OpenUrl
  24. 24.↵
    Emerick KM, Krantz ID, Kamath BM, et al. Intracranial vascular abnormalities in patients with Alagille syndrome. J Pediatr Gastroenterol Nutr 2005;41:99–107.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    Shefler AG, Chan MKH, Ostman-Smith I. Middle Aortic Syndrome in a Boy with Arteriohepatic Dysplasia (Alagille Syndrome). Pediatr Cardiol 1997;18:232–234.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Shrivastava R, Williams A, Mikhail A, et al. An unusual cause of hypertension and renal failure: a case series of a family with Alagille syndrome. Nephrol Dial Transplant 2010;25:1501–1506.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    Voykov B, Guenova E, Sturm E, et al. Alagille syndrome associated with myelinated retinal nerve fibers. Ophthalmologica 2009;223:348–350.
    OpenUrlPubMed
  28. 28.↵
    Wauters A, Dejagere T, Devriendt K, et al. Triangular face and vascular malformation. The links to renal failure. Nephrol Dial Transplant 2003;18:436–439.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Yucel H, Hoorntje SJ, Bravenboer B. Renal abnormalities in a family with Alagille syndrome. Neth J Med 2010;68:38–39.
    OpenUrlPubMed
  30. 30.↵
    Adachi T, Murakawa M, Uetsuki N, et al. Living related donor liver transplantation in a patient with severe aortic stenosis. Br J Anaesth 1999;83:488–490.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Jacquet A, Guiochon-Mantel A, Noël LH, et al. Alagille Syndrome in Adult Patients: It Is Never Too Late. Am J Kidney Dis 2007;49:705–709.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Kayhan A, Ilkhchoui Y, Venu N, et al. Multiple Abdominal Vascular Anomalies in a Patient with Alagille Syndrome. J Vasc Interv Radiol 2010;21:937–940.
    OpenUrlPubMed
  33. 33.↵
    Labrecque DR, Mitros FA, Nathan RJ, et al. Four Generations of Arteriohepatic Dysplasia. Hepatology 1982;2:467S–474S.
    OpenUrl
  34. 34.↵
    May L, Hanley FL, Connolly AJ, et al. Atherosclerosis causing recurrent catastrophic aortopulmonary shunt dehiscence in a patient with alagille syndrome. Pediatr Cardiol 2013;34:1945–1948.
    OpenUrl
  35. 35.↵
    Agarwal V. Recurrent coarctation in a patient with Alagille syndrome. Interact Cardiovasc Thorac Surg 2005;4:514–516.
    OpenUrlCrossRefPubMed
  36. 36.↵
    Mouzaki M, Nichter C, Qureshi M, et al. Idiopathic intracranial hypertension in two patients with alagille syndrome. J Child Neurol 2010;25:1006–1008.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Rocha R, Soro I, Leitão A, et al. Moyamoya vascular pattern in alagille syndrome. Pediatr Neurol 2012;47:125–128.
    OpenUrlPubMed
  38. 38.↵
    Santamaria R, Lopez-Aguilera J, Caldas RG De, et al. Vascular Abnormalities As Predominant Feature in Alagille Syndrome Patients With a Novel Mutation in Jag1 Gene. J Hypertens 2016;34:e180.
    OpenUrl
  39. 39.↵
    Schlosser H-G, Kerner T, Woiciechowsky C, et al. Multiple cerebral aneurysms and subarachnoid hemorrhage in a patient with Alagille syndrome. AJNR Am J Neuroradiol 2004;25:1366–1367.
    OpenUrlPubMed
  40. 40.↵
    Tobin WO, Connor GO, Doherty CP, et al. Low-flow retinopathy, anterograde amnesia and moya-moya phenomenon in alagille syndrome associated with a missence mutation in the Jagged 1 gene. J Neurol Neurosurg Psychiatry 2009;80.
  41. 41.↵
    Woolfenden AR, Albers GW, Steinberg GK, et al. Moyamoya Syndrome in Children With Alagille Syndrome: Additional Evidence of a Vasculopathy. Pediatrics 1999;103:505–508.
    OpenUrlFREE Full Text
  42. 42.↵
    Zweier C, Hammersen G, Behrens R, et al. Severe course of alagille syndrome associated with a novel NOTCH2 mutation. Genet Couns 2010;21:132–133.
    OpenUrl
  43. 43.↵
    Zhang W, Zhao XY, Huang J, et al. Alagille syndrome: an uncommon cause of intrahepatic cholestasis in adults. Rev Esp Enfermedades Dig 2019;111.
  44. 44.↵
    Kuang J, Zheng X-R, Zhang G-Y, et al. [Liver dysfunction for 8 years with hypertension for 1 week in an 8-year-old girl]. Zhongguo Dang Dai Er Ke Za Zhi 2019;21:282–286.
    OpenUrl
  45. 45.↵
    Sheth HS, Maldonado F, Lentz RJ. Two cases of Dieulafoy lesions of the bronchus with novel comorbid associations and endobronchial ablative management. Medicine (Baltimore) 2018;97:e9754.
    OpenUrl
  46. 46.↵
    Cheng K-W, Hunag J-J, Wang C-H, et al. Anesthetic Management of a Patient with Alagille’s Syndrome Undergoing Living Donor Liver Transplantation without Blood Transfusion. Chang Gung Med J 2004;27:449–453.
    OpenUrlPubMed
  47. 47.↵
    Yokoyama K, Minami T, Seki M, et al. A boy with Alagille syndrome coexisting with mid-aortic syndrome and renovascular hypertension. J Cardiol cases 2019;21:28–31.
    OpenUrl
  48. 48.↵
    Shimohata H, Imagawa K, Yamashita M, et al. An Adult Patient with Alagille Syndrome Showing Mainly Renal Failure and Vascular Abnormality without Liver Manifestation. Intern Med 2020;59:2907–2910.
    OpenUrl
  49. 49.↵
    Sanada Y, Naya I, Katano T, et al. Visceral artery anomalies in patients with Alagille syndrome. Pediatr Transplant 2019;23:1–7.
    OpenUrlCrossRef
  50. 50.↵
    Delaney S, O’Connor G, Reardon W, et al. Extracranial and Intracranial Vasculopathy With “Moyamoya Phenomenon” in Association With Alagille Syndrome. Front Neurol 2019;9:1–5.
    OpenUrl
  51. 51.↵
    Cowan JA, Barkhoudarian G, Yang LJS, et al. Progression of a posterior communicating artery infundibulum into an aneurysm in a patient with Alagille syndrome. Case report. J Neurosurg 2004;101:694–6.
    OpenUrl
  52. 52.↵
    Esther AR, Francesca C, Jose U. Neonatal hyperbilirrubinemia and prematurity as cause of green deciduous teeth. Curr Pediatr Res 2017;21:298–300.
    OpenUrl
  53. 53.↵
    Hia CPP, Quak SH, Quek SC. Mid aortic syndrome and Alagille syndrome. Heart 2004;90:1150 LP–1150.
    OpenUrlFREE Full Text
  54. 54.↵
    Connor SEJ, Hewes D, Ball C, et al. Alagille syndrome associated with angiographic moyamoya. Child’s Nerv Syst 2002;18:186–190.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    Funk M, Cohen M, Santana O. Alagille syndrome: An unusual presentation of an uncommon disease. South Med J 2010;103:1049–1051.
    OpenUrlPubMed
  56. 56.↵
    Hirai H, Santo Y, Kogaki S, et al. Successful stenting for renal artery stenosis in a patient with Alagille syndrome. Pediatr Nephrol 2005;20:831–833.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    Kavukçu S, Demir K, Soylu A, et al. A case of Takayasu disease with findings of incomplete Alagille syndrome. Rheumatol Int 2005;25:555–557.
    OpenUrlPubMed
  58. 58.↵
    Pavanello M, Severino M, D’Antiga L, et al. Pretransplant Management of Basilar Artery Aneurysm and Moyamoya Disease in a Child With Alagille Syndrome. Liver Transplant 2015;21:1227–1230.
    OpenUrl
  59. 59.↵
    Raas-Rothschild A, Shteyer E, Lerer I, et al. Jagged1 gene mutation for abdominal coarctation of the aorta in Alagille syndrome. Am J Med Genet 2002;112:75–78.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Ferreira-Magalhaes M. Renovascular hypertension related with alagille syndrome: A rare and severe clinical case. J Int Pediatr Nephrol Assoc 2014;29:1719.
    OpenUrl
  61. 61.↵
    Pati GK, Singh A, Nath P, et al. A 10-year-old child presenting with syndromic paucity of bile ducts (Alagille syndrome): a case report. J Med Case Rep 2016;10:1–5.
    OpenUrl
  62. 62.↵
    Nika A, Alexaki A, Koemtzidou E, et al. PP-205. An unusual presentation of Alagille syndrome in a premature baby. Early Hum Dev 2010;86:S99.
    OpenUrl
  63. 63.↵
    Shehata MR, Yagi S, Ogura Y, et al. Use of recipient left colic artery for arterial reconstruction during liver transplantation in alagille syndrome with vasculopathy: A case report. Transplantation 2012;93:e20–e21.
    OpenUrl
  64. 64.↵
    Tumialán LM, Dhall SS, Tomak PR, et al. Alagille Syndrome and Aneurysmal Subarachnoid Hemorrhage. Pediatr Neurosurg 2006;42:57–61.
    OpenUrlPubMed
  65. 65.↵
    Gaba RC, Shah RP, Muskovitz AA, et al. Synchronous moyamoya syndrome and ruptured cerebral aneurysm in Alagille syndrome. J Clin Neurosci 2008;15:1395–8.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    Moreau S, Bourdon N, Jokic M, et al. Alagille syndrome with cavernous carotid artery aneurysm. Int J Pediatr Otorhinolaryngol 1999;50:139–143.
    OpenUrlCrossRefPubMed
  67. 67.↵
    O’Connel D, Kaliaperumal C, Fanning N, et al. Superior cerebellar aneurysm causing subarachnoid haemorrhage in a 17-year-old with alagille syndrome. Br J Neurosurg 2012;26:287–289.
    OpenUrlCrossRefPubMed
  68. 68.↵
    Levin SE, Zarvos P, Milner S, et al. Arteriohepatic dysplasia: association of liver disease with pulmonary arterial stenosis as well as facial and skeletal abnormalities. Pediatrics 1980;66:876–883.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    Han S, Jeon TY, Hwang SM, et al. Imaging findings of Alagille syndrome in young infants: differentiation from biliary atresia. Br J Radiol 2017;90:20170406.
    OpenUrl
  70. 70.
    Bolt I, Spalinger J, Pfammatter J. Cardiac features in the presymptomatic period in a neonate with anomalous left coronary artery arising from the pulmonary trunk. Cardiol Young 2003;13:579–81.
    OpenUrlPubMed
  71. 71.↵
    Fitzgerald RT, Zuccoli G. Agenesis of the internal carotid artery: Associated malformations including a high rate of aortic and cardiac malformations. Pediatr Radiol 2012;42:1333–1338.
    OpenUrlCrossRefPubMed
  72. 72.↵
    Murthy GSG, Rana BS, Das A, et al. Alagille syndrome: A rare disease in an adolescent. Dig Dis Sci 2012;57:3035–3037.
    OpenUrlPubMed
  73. 73.↵
    Nishikawa A, Mori H, Takahashi M, et al. ALAGILLE’S SYNDROME: A Case with a Hamartomatous Nodule of the Liver. Pathol Int 1987;37:1319–1326.
    OpenUrl
  74. 74.↵
    Pascanu R, Sharma H. An Interesting Case of Alagille Syndrome. Am J Gastroenterol 2016;111:S854.
    OpenUrl
  75. 75.
    Villa E, Von Roenn N. A unique case of cirrhosis due to Alagille syndrome. In: American Journal of Gastroenterology.Vol 109.; 2014:S356.
    OpenUrl
  76. 76.↵
    Lopez RN, Rawahi Y Al, Stormon M, et al. Hepatobiliary and Pancreatic: Hepatic arterioportal fistula: A novel and treatable feature of Alagille syndrome. J Gastroenterol Hepatol 2018;34:633.
    OpenUrl
  77. 77.↵
    Lorenzo-Zúñiga V, Morillas RM, Planas R, et al. [Presinusoidal portal hypertension due to portal thrombosis in a patient with Alagille’s syndrome]. Gastroenterol Hepatol 2003;26:294–6.
    OpenUrlPubMed
  78. 78.↵
    DeSena HC, Ramaciotti C, Nugent AW. Atherotome dislodgement and successful retrieval during cutting balloon pulmonary angioplasty. Circ Cardiovasc Interv 2012;5:37–38.
    OpenUrl
  79. 79.↵
    Rachmel A, Zeharia A, Neuman-Levin M, et al. Alagille syndrome associated with Moyamoya disease. Am J Med Genet 1989;33:89–91.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.
    Micaglio E, Andronache AA, Carrera P, et al. Novel JAG1 Deletion Variant in Patient with Atypical Alagille Syndrome. Int J Mol Sci 2019;20.
  81. 81.↵
    Zheng Y, Peng Y, Zhang S, et al. Capillary Malformation-Arteriovenous Malformation Combined Alagille Syndrome in a Patient With Double Gene Variations of RASA1 and NOTCH2. Front Genet 2019;10:1–7.
    OpenUrlCrossRef
  82. 82.↵
    De Franchis R, Eisen GM, Laine L, et al. Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology 2008;47:1595–1603.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    Radi E, Formichi P, Di Maio G, et al. Oxidative stress-induced apoptosis in two patients with Alagille syndrome. J Neurol Sci 2011;308:49–56.
    OpenUrlPubMed
  84. 84.↵
    Lim MR, Lee SY, Kim DS, et al. A Case of Moyamoya Disease in a Child with Alagille Syndrome. J Korean Pediatr Soc 2003;46:86–90.
    OpenUrl
  85. 85.↵
    Hoffenberg EJ, Narkewicz MR, Sondheimer JM, et al. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995;127:220–224.
    OpenUrlCrossRefPubMedWeb of Science
  86. 86.↵
    Kazi R, Fakhoury J, Beck R. A Case of Recurrent Intracranial Bleeds in the Setting of Alagille Syndrome. In: Pediatrics.Vol 142.; 2018.
  87. 87.↵
    Doberentz E, Kuchelmeister K, Madea B. Subarachnoid hemorrhage due to aneurysm rupture in a young woman with Alagille syndrome - A rare cause of sudden death. Leg Med 2015;17:309–312.
    OpenUrl
  88. 88.↵
    Fiorda-Diaz J, Shabsigh M, Dimitrova G, et al. Perioperative Management of Subarachnoid Hemorrhage in a Patient with Alagille Syndrome and Unrepaired Tetralogy of Fallot: Case Report. Front Surg 2017;4:72.
    OpenUrl
  89. 89.↵
    Frongillo F, Bianco G, Silvestrini N, et al. Acute Liver Failure in an Adult, a Rare Complication of Alagille Syndrome: Case Report and Brief Review. Transplant Proc 2015;47:2179–2181.
    OpenUrl
  90. 90.↵
    Agrawal S, Chennuri V, Agrawal P. Genetic Diagnosis in an Indian Child with Alagille Syndrome. Indian J Pediatr 2015;82:653–654.
    OpenUrl
  91. 91.↵
    Vorstman EBA, Anslow P, Keeling DM, et al. Brain haemorrhage in five infants with coagulopathy. Arch Dis Child 2003;88:1119–21.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    Adamson GT, Peng LF, Feinstein JA, et al. Pulmonary hemorrhage in children with Alagille syndrome undergoing cardiac catheterization. Catheter Cardiovasc Interv 2020;95:262–269.
    OpenUrl
  93. 93.↵
    DesRoches J, McKeen DM, George RB, et al. VAGINAL DELIVERY IN PARTURIENT WITH ALAGILLE-WATSON SYNDROME. In: Canadian Journal of Anesthesia.Vol 60.; 2013:S46.
    OpenUrl
  94. 94.↵
    Békássy AN, Garwicz S, Wiebe T, et al. Hepatocellular carcinoma associated with arteriohepatic dysplasia in a 4‐ year‐old girl. Med Pediatr Oncol 1992;20:78–83.
    OpenUrlPubMed
  95. 95.
    Shehata MR, Yagi S, Ogura Y, et al. Use of recipient left colic artery for arterial reconstruction during liver transplantation in alagille syndrome with vasculopathy: A case report. Transplantation 2012;93:20–21.
    OpenUrl
  96. 96.↵
    Schoen K, Ribeiro CM de F, Goncalves MC, et al. Hepatocellular carcinoma in an adult with Alagille syndrome: case report and literature review. Radiol case reports 2020;16:90–93.
    OpenUrl
  97. 97.↵
    Englert C, Grabhorn E, Burdelski M, et al. Liver transplantation in children with Alagille syndrome: Indications and outcome. Pediatr Transplant 2006;10:154–158.
    OpenUrlCrossRefPubMed
  98. 98.↵
    Akagi K, Tanaka T, Baba S. Successful living donor liver transplantation after stent implantation in a patient with Alagille syndrome and severe bilateral pulmonary artery stenosis. Cardiol Young 2018;28:1465–1467.
    OpenUrl
  99. 99.↵
    Kloek JJ, Heger M, Van Der Gaag NA, et al. Effect of Preoperative Biliary Drainage on Coagulation and Fibrinolysis in Severe Obstructive Cholestasis. J Clin Gastroenterol 2010;44:646–652.
    OpenUrlPubMed
  100. 100.↵
    Sullivan BP, Weinreb PH, Violette SM, et al. The Coagulation System Contributes to αVβ6 Integrin Expression and Liver Fibrosis Induced by Cholestasis. Am J Pathol 2010;177:2837–2849.
    OpenUrlCrossRefPubMedWeb of Science
  101. 101.↵
    Yilmaz S, Turhan T, Mutluer S, et al. The Association of Alagille Syndrome and Craniosynostosis. Pediatr Neurol 2013;48:146–148.
    OpenUrl
  102. 102.↵
    Hankeova S, Salplachta J, Zikmund T, et al. DUCT reveals architectural mechanisms contributing to bile duct recovery in a mouse model for Alagille syndrome. Elife 2021;10:1–29.
    OpenUrl
  103. 103.↵
    Benedito R, Roca C, Sörensen I, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009;137:1124–35.
    OpenUrlCrossRefPubMedWeb of Science
  104. 104.↵
    Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Investig Ophthalmol Vis Sci 2010;51:2813–2826.
    OpenUrlAbstract/FREE Full Text
  105. 105.↵
    Pedrosa AR, Trindade A, Fernandes AC, et al. Endothelial jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1. Arterioscler Thromb Vasc Biol 2015;35:1134–1146.
    OpenUrlAbstract/FREE Full Text
  106. 106.↵
    Qiao CZ, Richter GT, Pan WJ, et al. Extracranial arteriovenous malformations: from bedside to bench. Mutagenesis 2019;34:299–306.
    OpenUrl
  107. 107.↵
    Secomb TW. Hemodynamics. Compr Physiol 2016;6:975–1003.
    OpenUrl
  108. 108.↵
    Han HC. Twisted blood vessels: Symptoms, etiology and biomechanical mechanisms. J Vasc Res 2012;49:185–197.
    OpenUrlCrossRefPubMed
  109. 109.↵
    Haigh JJ, Morelli PI, Gerhardt H, et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling º. Dev Biol 2003;262:225–241.
    OpenUrlCrossRefPubMedWeb of Science
  110. 110.↵
    Wang Y, Rattner A, Zhou Y, et al. Norrin / Frizzled4 Signaling in Retinal Vascular Development and Blood Brain Barrier Plasticity. Cell 2012;151:1332–1344.
    OpenUrlCrossRefPubMedWeb of Science
  111. 111.
    Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707–710.
    OpenUrlCrossRefPubMedWeb of Science
  112. 112.↵
    Kalimo H, Ruchoux MM, Viitanen M, et al. CADASIL: A common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol 2002;12:371–384.
    OpenUrlCrossRefPubMedWeb of Science
  113. 113.↵
    High FA, Lu MM, Pear WS, et al. Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc Natl Acad Sci U S A 2008;105:1955–9.
    OpenUrlAbstract/FREE Full Text
  114. 114.↵
    Scheppke L, Murphy EA, Zarpellon A, et al. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement memb. Blood 2012;119:2149–2158.
    OpenUrlAbstract/FREE Full Text
  115. 115.↵
    Doberentz E, Kuchelmeister K, Madea B. Subarachnoid hemorrhage due to aneurysm rupture in a young woman with Alagille syndrome - A rare cause of sudden death. Leg Med (Tokyo) 2015;17:309–312.
    OpenUrl
  116. 116.↵
    Armulik A, Genove G, Mäe M, et al. Pericytes regulate the blood–brain barrier. Nat Lett 2010;468:557–561.
    OpenUrl
  117. 117.↵
    Hansson EM, Lanner F, Das D, et al. Control of Notch-ligand endocytosis by ligand-receptor interaction. J Cell Sci 2010;123:2931–42.
    OpenUrlAbstract/FREE Full Text
  118. 118.↵
    Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685–693.
    OpenUrlCrossRefPubMedWeb of Science
  119. 119.↵
    Sanes JR, Masland RH. The Types of Retinal Ganglion Cells: Current Status and Implications for Neuronal Classification. Annu Rev Neurosci 2015;38:221–246.
    OpenUrlCrossRefPubMed
  120. 120.↵
    El-Koofy NM, El-Mahdy R, Fahmy ME, et al. Alagille syndrome: clinical and ocular pathognomonic features. Eur J Ophthalmol 2011;21:199–206.
    OpenUrlPubMed
  121. 121.↵
    Casado A, Rebolleda G, Guerrero L, et al. Measurement of retinal nerve fiber layer and macular ganglion cell – inner plexiform layer with spectral-domain optical coherence tomography in patients with optic nerve head drusen. Graefes Arch Clin Exp Ophthalmol 2014;252:1653–1660.
    OpenUrl
  122. 122.↵
    Howell GR, Libby RT, Jakobs TC, et al. Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol 2007;179:1523–1537.
    OpenUrlAbstract/FREE Full Text
  123. 123.↵
    O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112–123.
    OpenUrlCrossRefPubMedWeb of Science
  124. 124.↵
    Berard E, Sarles J, Triolo V, et al. Renovascular hypertension and vascular anomalies in Alagille syndrome. Pediatr Nephrol 1998;12:121–124.
    OpenUrlCrossRefPubMedWeb of Science
  125. 125.↵
    Kamath BM, Spinner NB, Rosenblum ND. Renal involvement and the role of Notch signalling in Alagille syndrome. Nat Rev Nephrol 2013;9:409–18.
    OpenUrlCrossRefPubMed
  126. 126.↵
    Johns C, Gavras I, Handy DE, et al. Models of Experimental Hypertension in Mice. Hypertension 1996;28:1064–1069.
    OpenUrlCrossRef
  127. 127.↵
    Machuca-Parra AI, Bigger-Allen AA, Sanchez A V., et al. Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL. J Exp Med 2017;214:2271–2282.
    OpenUrlAbstract/FREE Full Text
  128. 128.↵
    Fahnehjelm KT, Fischler B, Martin L, et al. Occurrence and pattern of ocular disease in children with cholestatic disorders. Acta Ophthalmol 2011;89:143–150.
    OpenUrlPubMed
  129. 129.↵
    Hingorani M, Nischal KK, Davies A, et al. Ocular Abnormalities in Alagille Syndrome. Ophthalmology 1999;106:330–337.
    OpenUrlCrossRefPubMedWeb of Science
  130. 130.↵
    Nischal KK, Hingorani M, Bentley CR, et al. Ocular Ultrasound in Alagille Syndrome: A New Sign. Ophthalmology 1997;104:79–85.
    OpenUrlPubMedWeb of Science
  131. 131.↵
    Makino S, Ohkubo Y, Tampo H. Optical coherence tomography and fundus autofluorescence imaging study of chorioretinal atrophy involving the macula in Alagille syndrome. Clin Ophthalmol 2012;6:1445–1448.
    OpenUrlPubMed
  132. 132.↵
    Alten F, Motte J, Ewering C, et al. Multimodal retinal vessel analysis in CADASIL patients. PLoS One 2014;9:1–10.
    OpenUrlCrossRefPubMed
  133. 133.↵
    Nelis P, Kleffner I, Burg MC, et al. OCT-Angiography reveals reduced vessel density in the deep retinal plexus of CADASIL patients. Sci Rep 2018;8:1–7.
    OpenUrlCrossRefPubMed
  134. 134.↵
    Martin G, Wefelmeyer KL, Bucher F, et al. Arteriovenous crossing in retinal vessels of mice, rats, and pigs. Mol Vis 2020;26:731–741.
    OpenUrl
  135. 135.↵
    Fahnehjelm KT, Wide K, Ygge J, et al. Visual and ocular outcome in children after prenatal exposure to antiepileptic drugs. Acta Ophthalmol Scand 1999;77:530–535.
    OpenUrlPubMed
  136. 136.↵
    Thakurdas SM, Lopez MF, Kakuda S, et al. Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi). Hepatology 2016;63:550–565.
    OpenUrlCrossRefPubMed
  137. 137.↵
    Clotman F, Libbrecht L, Gresh L, et al. Hepatic artery malformations associated with a primary defect in intrahepatic bile duct development. J Hepatol 2003;39:686–692.
    OpenUrlCrossRefPubMed
  138. 138.↵
    Lawson ND, Scheer N, Pham VN, et al. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 2001;128:3675–83.
    OpenUrlAbstract/FREE Full Text
  139. 139.
    Limbourg A, Ploom M, Elligsen D, et al. Notch Ligand Delta-Like 1 Is Essential for Postnatal Arteriogenesis. 2016:363–372.
  140. 140.↵
    Henshall TL, Keller A, He L, et al. Notch3 Is Necessary for Blood Vessel Integrity in the Central Nervous System. Arter Thromb Vasc Biol 2014:409–420.
  141. 141.↵
    High FA, Lu MM, Pear WS, et al. Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc Natl Acad Sci U S A 2008;105:1955–1959.
    OpenUrlAbstract/FREE Full Text
  142. 142.↵
    Cheung CYL, Zheng Y, Hsu W, et al. Retinal vascular tortuosity, blood pressure, and cardiovascular risk factors. Ophthalmology 2011;118:812–818.
    OpenUrlCrossRefPubMedWeb of Science
  143. 143.
    Gekeler F, Shinoda K, Junger M, et al. Familial Retinal Arterial Tortuosity Associated With Tortuosity in Nail Bed Capillaries Familial. Arch Ophthalmol 2006;124:1492–1494.
    OpenUrlCrossRefPubMedWeb of Science
  144. 144.
    Hayreh SS, Servais GE, Virdi PS. Retinal arteriolar changes in malignant arterial hypertension. Ophthalmologica 1989;198:178–196.
    OpenUrlCrossRefPubMedWeb of Science
  145. 145.↵
    Dougherty G, Johnson MJ, Wiers MD. Measurement of retinal vascular tortuosity and its application to retinal pathologies. Med Biol Eng Comput 2010;48:87–95.
    OpenUrlCrossRefPubMed
  146. 146.↵
    Kim BJ, Fulton AB. The genetics and ocular findings of Alagille syndrome. Semin Ophthalmol 2007;22:205–10.
    OpenUrlCrossRefPubMed
  147. 147.↵
    Kim BJ, Fulton AB. Seminars in Ophthalmology The Genetics and Ocular Findings of Alagille Syndrome The Genetics and Ocular Findings of Alagille Syndrome. Semin Ophthalmol 2007;224.
  148. 148.↵
    Etminan N, Chang HS, Hackenberg K, et al. Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage According to Region, Time Period, Blood Pressure, and Smoking Prevalence in the Population: A Systematic Review and Meta-analysis. JAMA Neurol 2019;76:588–597.
    OpenUrlPubMed
  149. 149.↵
    Pakvasa M, Haravu P, Boachie-Mensah M, et al. Notch signaling: Its essential roles in bone and craniofacial development. Genes Dis 2021;8:8–24.
    OpenUrl
  150. 150.↵
    Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci 2011;120:357–375.
    OpenUrlCrossRefPubMed
  151. 151.↵
    Reagan AM, Gu X, Paudel S, et al. Age-related focal loss of contractile vascular smooth muscle cells in retinal arterioles is accelerated by caveolin-1 deficiency. Neurobiol Aging 2018;71:1–12.
    OpenUrl
  152. 152.↵
    Wang G-X, Zhang D, Wang Z-P, et al. Risk factors for ruptured intracranial aneurysms. Indian J Med Res 2018;147:51–57.
    OpenUrl
  153. 153.↵
    Wirtschafter JD. OPTIC NERVE AXONS AND ACQUIRED ALTERATIONS IN THE APPEARANCE OF THE OPTIC DISC. Trans Am Ophthalmol Soc 1983;91:1034–1089.
    OpenUrl
  154. 154.↵
    Narula P, Gifford J, Steggall MA, et al. Visual Loss and Idiopathic Intracranial Hypertension in Children With Alagille Syndrome. J Pediatr Gastroenterol nu 2006;43:348–352.
    OpenUrl
  155. 155.↵
    Jin S, Mutvei a P, Chivukula I V, et al. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. Oncogene 2013;32:4892–902.
    OpenUrlCrossRefPubMedWeb of Science
Back to top
PreviousNext
Posted April 14, 2021.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Bleeding in patients and mice with Alagille syndrome: sex differences and risk factors
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bleeding in patients and mice with Alagille syndrome: sex differences and risk factors
Simona Hankeova, Noemi Van Hul, Jakub Laznovsky, Naomi Hensen, Elvira Verhoef, Tomas Zikmund, Feven Dawit, Michaela Kavkova, Jakub Salplachta, Liting Li, Marika Sjöqvist, Bengt R. Johansson, Mohamed Hassan, Vitezslav Bryja, Urban Lendahl, Andrew Jheon, Jian She Wang, Florian Alten, Kristina Teär Fahnehjelm, Björn Fischler, Jozef Kaiser, Emma R. Andersson
bioRxiv 2021.04.13.439679; doi: https://doi.org/10.1101/2021.04.13.439679
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Bleeding in patients and mice with Alagille syndrome: sex differences and risk factors
Simona Hankeova, Noemi Van Hul, Jakub Laznovsky, Naomi Hensen, Elvira Verhoef, Tomas Zikmund, Feven Dawit, Michaela Kavkova, Jakub Salplachta, Liting Li, Marika Sjöqvist, Bengt R. Johansson, Mohamed Hassan, Vitezslav Bryja, Urban Lendahl, Andrew Jheon, Jian She Wang, Florian Alten, Kristina Teär Fahnehjelm, Björn Fischler, Jozef Kaiser, Emma R. Andersson
bioRxiv 2021.04.13.439679; doi: https://doi.org/10.1101/2021.04.13.439679

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Developmental Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (3592)
  • Biochemistry (7562)
  • Bioengineering (5508)
  • Bioinformatics (20762)
  • Biophysics (10309)
  • Cancer Biology (7967)
  • Cell Biology (11625)
  • Clinical Trials (138)
  • Developmental Biology (6598)
  • Ecology (10190)
  • Epidemiology (2065)
  • Evolutionary Biology (13594)
  • Genetics (9532)
  • Genomics (12834)
  • Immunology (7917)
  • Microbiology (19525)
  • Molecular Biology (7651)
  • Neuroscience (42027)
  • Paleontology (307)
  • Pathology (1254)
  • Pharmacology and Toxicology (2196)
  • Physiology (3263)
  • Plant Biology (7029)
  • Scientific Communication and Education (1294)
  • Synthetic Biology (1949)
  • Systems Biology (5422)
  • Zoology (1114)